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ABSTRACT 
The function of skeletal muscle is an essential component of animal physiology and daily life. 
Hereditary muscle diseases are comparatively rare in humans, but often very severe.  The 
disease causes are heterogeneous, defects in nerves, intracellular components, structural 
proteins and the contractile apparatus can be involved. Genetic linkage analyses have 
revealed associations between some genetic defects and muscle diseases. Causal relationships 
have been established in some animal models, but the exact function of several of the 
genes/proteins in the muscle and their roles in pathogenesis of the diseases have not been 
fully explored. The general aim of the thesis was to develop and analyze muscle disease 
models in the zebrafish larvae using a combined genetic and physiological approach, 
focusing on cytoskeletal/structural proteins and to explore different therapeutic options. In 
Paper I, desmin, which is a key intermediate filament protein, was knocked down in larval 
muscles by about 50 % using morpholino antisense oligonucletotide injection. This 
knockdown model had a significant impairment in muscle structure and decreased active 
force. X-ray diffraction analysis revealed swelling of the filament lattice after desmin 
knockdown, suggesting a role of desmin in the lateral anchoring of the contractile apparatus. 
Moreover, the vulnerability to eccentric contractions was lower after desmin knockdown 
suggesting that desmin is involved in lateral force transmission in the muscle cells.  In Paper 
II, the zebrafish dystrophin null Sapje mutant, a model for Duchenne Muscular Dystrophy 
(DMD), was characterized. These mutant larvae had structural changes and compromised cell 
membranes, observed early during development (3 days post fertilization, dpf). Active force 
was significantly lower (about 50 % of that in the normal siblings).  Two-day treatment with 
Ataluren, a compound causing read through of premature stop codons, partially restored the 
protein expression of dystrophin in the Sapje mutants. This was accompanied by a significant 
improvement of muscle structure and active force. The effect of Ataluren on active force 
revealed a bell-shaped dose dependency, similar to that suggested in initial clinical trials. The 
pathogenesis of DMD is complex, several factors can be involved. The contribution of the 
mechanical linkage provided by dystrophin/dystrophin-glycoprotein complex in the disease 
development of muscular dystrophin was examined in Paper III. Sapje mutants were fully 
immobilized by BTS (an actomyosin inhibitor) from 18 hours after fertilization until 4 dpf. 
The structural damage, as assayed by birefringence, was completely abolished by 
immobilization. To further validate the concept in another dystrophic model, Candyfloss 
mutants that were laminin-α2 chain null, were treated using the same protocol. These mutants 
which had significantly impaired structure were also rescued by immobilization. Following 
washout of BTS and active swimming, structural damage developed supporting mechanical 
contractions as a primary factor in the development of structural changes in muscular 
dystrophy. In Paper IV, the role of a sarcomeric protein, myosin binding protein C (MyBPC) 
was examined in the skeletal muscle. The skeletal isoforms, were knocked down in larvae. 
Partial removal of the fast type (MyBPC-2) resulted in a severe form of skeletal myopathy 
with activated degeneration/regeneration processes. Significant alterations were observed in 
the sarcomeric structure suggesting that MyBPC-2 is required for normal sarcomere 
assembly. The active force was significantly lower and the maximal shortening velocity was 
increased after MyBPC-2 knockdown, indicating that the close interaction between MyBPC-
2 and the contractile filaments affects cross-bridge interaction. It is expected that a human 
myopathy associated with MyBPC-2 alterations, if present, would be severe with significant 
alterations in skeletal muscle structure and function. In general, the papers included in the 
thesis show that models for human muscle disease in the zebrafish can be analyzed with a 
clinically relevant functional read out, that novel therapeutic options can be examined in these 
models and that possible new muscle diseases associated with altered expression of structural 
muscle proteins can be identified.
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1 INTRODUCTION 
1.1 SKELETAL MUSCLES AND SKELETAL MUSCLE DISEASE 
Muscles are essential for the physiology of humans and other animals. The three main types, 
skeletal, cardiac and smooth muscles have key functions in the body. The cardiac muscle 
sustains the pumping activity of the heart and the smooth muscles maintain tone in the wall of 
hollow organs like blood vessels and intestines. The skeletal muscle supports locomotion, 
posture maintenance, respiratory ventilation and heat generation (Marieb, 1995). The skeletal 
muscle is cross-striated, when observed in the microscope, due to its sarcomeric organization, 
and the contraction is achieved by shortening of the sarcomeres caused by interaction 
between the contractile myosin and actin filaments, as described by “the sliding filament 
model” (Huxley and Niedergerk, 1954; Huxley and Hanson, 1954). When a muscle is 
activated via its motor neurons, myosin cross-bridges attach and exert power strokes to 
produce force and shortening. This process is regulated by intracellular Ca2+ binding to 
troponin on the thin filaments, which leads to activation of the actin-myosin interaction 
(Cooke, 1997). The contractile proteins, actin and myosin, constituting the thin and thick 
filaments, are anchored in a complex cytoskeleton which provides mechanical contacts in the 
cell, and also participates in cellular signaling. 
Although skeletal muscle function is an important component in daily life, it can also be 
affected in several muscle diseases. In general, the causes for muscle disease are 
heterogeneous, from alterations in nerves, mitochondria, sarcoplasmic reticulum, to nuclei 
and other intracellular components (Goebel, 2011; Laing, 2012). The inheritable muscle 
diseases are relatively rare, but often devastating where patients become disabled often at an 
early age and can die prematurely. The disease prevalence is variable among different disease 
subtypes and the geographic locations, and a recent study on genetic muscle disease showed 
an overall prevalence of 37.0/100 000 in Northern England (Norwood et al., 2009). The 
cytoskeletal proteins, interacting or regulating the contractile apparatus, are often engaged in 
hereditary muscle disease, where mutations give rise to low protein content or aberrant 
protein function (Emery, 2002; Goebel, 2011). For the many forms of hereditary muscle 
disease hardly any effective treatments are available.  
Today, clinical analysis of genetic mutations, with screening and identification of novel 
candidate genes for muscle disease, is rapidly developing. However, to seek and confirm 
causal relationships, between mutation and disease, mechanistic studies are needed (Laing, 
2012). For understanding the role of the many muscle proteins (normal and mutated) 
involved in muscle disease, different animal models of muscle disease and new platforms for 
high throughput therapeutic screening have to be developed. 
With this background, the thesis work was initiated to establish the zebrafish model for 
studying muscle protein function; and to examine pathological mechanisms and therapeutic 
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options in skeletal muscle diseases. In this introduction, I present a background on the 
skeletal muscle diseases addressed in the Papers I-IV included in the thesis.  
Figure 1 depicts the contractile components, with a sarcomere, thick and thin filaments, in a 
muscle cell. The sarcomere and contractile filaments are connected via cytoskeletal proteins, 
some of which shown in the illustration. Desmin and the desminopathies introduced in 
Section 1.2.1 was the topic of Paper I. Dystrophin and Duchenne Muscular Dystrophy are 
introduced in Section 1.2.2 (Papers II, III), Laminin and Merosin-deficient congenital 
muscular dystrophy in Section 1.2.3 (Papers II, III) and Myosin Binding Protein C 
(MyBPC) in Section 1.2.4 (Paper IV).        
 
 
Figure 1. Schematic view of some key proteins and associated structures in the skeletal muscle cell.  
 
1.2 SKELETAL MUSCLE DISEASES AND RELATED PROTEINS 
1.2.1 Myofibrillar myopathy and Desminopathy 
Myofibrillar myopathies (MFMs) are a large heterogeneous group of chronic neuromuscular 
disorders sharing similar pathological features, including degradation of the myofibrils, 
accumulation of degraded products as well as ectopic expression of several proteins (Selcen 
and Engel, 2011). These diseases are rare in humans, but often severe with cardiac and 
respiratory involvement. The onset in patients varies between infant to adulthood, and the 
clinical phenotype has a large spectrum. The inheritance has been reported as autosomal 
dominant or recessive in most cases, and causative mutations in multiple genes have been 
  3 
identified. Genes and encoding proteins involved in MFMs mainly include desmin, αB-
crystallin, myotilin, filamin C, ZASP, FHL1, BAG3, and myotilin (Schröder and Schoser, 
2009). 
Among the several protein candidates causing MFMs, desmin is the most commonly 
involved. Missense mutations have been identified in human desmin gene (DES), and being 
shown to be responsible for fragility of the myofibrils (Dalakas et al., 2000). Moreover, the 
locations of these mutations in DES are often related to the clinical phenotypes, e.g., 
mutations on 2B segment of DES primarily reveal a skeletal myopathy whereas the defects on 
1B segment are closely related with cardiomyopathy (Goldfarb et al., 1998). The desmin-
related myopathies constitute a distinct subgroup of MFMs, where the muscle weakness 
usually occurs in distal muscles and progresses to the proximal. Cardiomyopathy and 
respiratory impairment is often involved. Microscopic examination reveals general signs of 
degenerative myopathy, and, like in other MFMs, accumulation of protein deposits is a 
characteristic pathological finding in the desminopathy. The intracellular protein aggregates 
are often found along the Z-line, and formed by the mutated desmin proteins or other 
myofibrillar proteins (Goldfarb et al., 2008).  
1.2.1.1 Desmin and Intermediate filaments 
Desmin is a key member of the intermediate filament (IF) proteins, specifically expressed in 
muscle tissues forming the 10-nm filaments. In humans, the desmin protein is a 470-aa 
protein with molecular weight of ~50 kDa. The protein is highly conserved among different 
species. It is essential for the scaffolding structure around the Z-disk in striated muscles, 
thereby linking the contractile machinery to the cell membrane, having an important role in 
maintaining myofibrillar integrity and in transmitting forces in the muscle tissues (Lazarides, 
1980). Moreover, the structural bridging by desmin IF also anchors several intracellular 
organelles and the nuclei in muscle cells, further providing integration in the whole cell 
(Tokuyasu et al., 1983). 
1.2.1.2 Human and mouse studies on desminopathy 
In human desminopathies, most of the cases are caused by dominant negative mutations in 
desmin or αB-crystallin and exhibit the pathological hallmark of the intra-sarcoplasmic 
protein accumulation (Goldfarb et al., 2008). The insoluble protein deposits are reported to be 
toxic to the muscle cells, leading to the progression of muscle degeneration. However, one 
patient case has been reported (Muñoz-Mármol et al., 1998), where a homozygous or 
hemizygous deletion in the DES gene resulted in a severe myopathy, thus suggesting that low 
desmin content also is a pathological mechanism.   
Several studies on mouse models for desminopathies have been performed, based on the 
desmin knockout (DES-/-) mouse created in 1996 (Li et al., 1996; Milner et al., 1996). The 
DES-/- mice are viable and essentially normal without a severely impaired general 
phenotype. The complete loss of desmin did not affect the development/differentiation of the 
muscle cells, but resulted in a severe myopathy affecting all types of muscle tissues including 
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skeletal, cardiac and smooth muscles (Li et al., 1996). Specifically, the DES-/- skeletal 
muscles had severely disrupted muscle architecture, widened lattice spacing, significantly 
reduced tension generation as well as altered vulnerability to eccentric contractions (Balogh 
et al., 2003; Milner et al., 1996; Sam et al., 2000; Wieneke et al., 2000). However, in the 
heterozygous animals (DES+/-) where the protein content was significantly lower, no major 
pathology was detected in the muscles (Li et al., 1997; Milner et al., 1996). The difference 
between DES+/- and DES-/- mice thus suggests that a complete ablation of desmin protein is 
required for the pathogenesis of desminopathy in the mouse model. It should be noted that 
unlike the human desminopathy, the DES-/- mice did not show any protein deposits. 
Transgenic mice carrying various DES mutations have also been investigated to understand 
the specific role of human mutations and encoding truncated proteins. It has been reported 
that over-expression of wild-type desmin did not show any alterations; whereas the 
introduction of a 7–amino acid deletion (R173 through E179) in desmin resulted in a severe 
cardiomyopathy with the appearance of aggregates within the muscle cells (Wang et al., 
2001). Taken together, substantial knowledge on desminopathy has been obtained from 
human and mouse studies, but it still remains unclear if the alterations in desmin protein 
content would play a role in the disease or if the aggregates are the main mechanism. The 
comparatively mild phenotype in the mice models should also be taken into consideration, 
possibly suggesting that alternative animal models are needed.  
1.2.2 Duchenne muscular dystrophy (DMD) 
The Duchenne muscular dystrophy (DMD), first clinically described in mid-19th century, is 
the most common and severe myopathy in childhood. The clinical onset is early in life, 
between 2-4 years of age, then with progress leading to a severe disability with 
immobilization and need for wheelchair during puberty, and often death at 15–25 years of 
age. The muscle weakness affects mainly proximal muscles, and often includes a cardiac 
dysfunction (Jay and Vajsar, 2001). The disease is X-chromosome linked and affecting 
~1/3500 boys. The muscle fiber size is often variable in DMD biopsies and cell necrosis, 
macrophage invasion and increased connective tissue are usually seen in the affected muscle 
tissues. Serum creatine kinase values are elevated, suggesting compromised cell membrane 
(Emery, 2002). 
The primary cause for DMD is the defect in the dystrophin protein (Hoffman et al., 1987). 
The ultimate consequence of the genetic mutations in DMD is the complete absence of 
functional dystrophin, while the reduction or partial expression of normal dystrophin lead to a 
milder form as known as Becker Muscular Dystrophy (BMD). Recently, up to 4700 
mutations have been reported in the Leiden DMD mutation database (Aartsma-Rus et al., 
2006). The genetic alterations in the DMD gene are highly heterogeneous, including 
intragenic deletions (65%), duplications (5% to 15%), nonsense point mutations, frame-shift 
mutations (Muntoni et al., 2003). 
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1.2.2.1 Conventional treatment for DMD and Ataluren  
Currently, there is no effective cure for DMD; most of the treatments are focused on the 
disease management. The standard clinical drug is glucocorticoids, used mainly to relieve the 
symptoms and slow down the disease progression, but also introducing secondary side 
effects. Novel therapeutics have shown some promise and undergone further investigations, 
including adeno-associated virus mediated gene therapy, exon-skipping agents and read-
through compounds (Beytía et al., 2012). 
Non-sense mutations, introducing premature stop codons occur in 10-15% of all DMD 
patients. It has been found that some aminoglycosides (e.g. gentamycin) promote read-
through of pre-mature translation stop codons, and that this compound is effective in the 
dystrophic mdx mice carrying a point mutation in the dystrophin gene (Barton-Davis et al., 
1999). The dystrophin levels were significantly increased after 14-day gentamycin treatment 
and were accompanied by recovery in force generation. The aminoglycosides have however 
side effects with nephrotoxicty and ototoxicity, preventing long term use in human dystrophy.  
Ataluren, also known as PTC-124, is a small-molecular drug identified in chemical screening 
for suppressing the nonsense mutations and promoting the read-through of pre-mature 
termination in mRNA. The read-trough effect of Ataluren is more prominent than that of the 
aminoglycosides, and with much less toxicity (Welch et al., 2007). It was reported to interact 
with the ribosome during protein translation, promoting the read-through of premature 
termination caused by nonsense mutations only, and not interfering with the normal stop 
codons. In addition to initial tests in vitro, it has also been introduced into several mouse 
models with nonsense mutations associated with human genetic disorders in vivo, including 
Duchenne muscular dystrophy (DMD), cystic fibrosis (CF) and haemophilia. For the 
treatment of DMD, an initial phase II study was unfortunately unsuccessful, possibly because 
of a small material and inclusion criteria. The drug showed no toxicity, but the results 
suggested a complex dose dependency with no effects of higher doses (Peltz et al., 2013). 
More research, including our Paper II, has addressed this problem and Ataluren has now 
entered in phase III clinical trials (Bushby et al., 2014). 
1.2.2.2 Dystrophin and Dystrophin-glycoprotein complex (DGC) 
DMD/dystrophin gene is the largest gene identified in the human genome, and the encoding 
dystrophin protein is about 427 kDa in weight (Kunkel et al., 1989). The expression is mainly 
in the striated muscle tissues. Dystrophin is a large cytoskeletal protein, located closely to the 
sarcoplasmic surface of the sarcolemma; together with trans-membrane proteins (e.g. 
sarcoglycans, dystroglycan) and other partners (e.g. dystrobrevin) to form a condensed 
complex, which provides attachment between the cytoskeleton and the cell membrane. At the 
extracellular matrix, the DGC also adheres to laminin via α-dystroglycan, and further 
stabilizes the integrity of the cells (Davies and Nowak, 2006). In addition to the mechanical 
role, dystrophin and its partners in the DGC are also suggested to play an important role in 
signaling relay/transduction between matrix and nucleus. It has been proposed that the 
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interacting signaling proteins included calmodulin, CaM kinase II, and mitogen-activated 
protein kinase kinase 2, nNOS etc. (Bhatnagar and Kumar, 2010). Considering the structural 
and functional importance of the dystrophin and DGC, the pathogenic mechanisms of DMD 
have been considered very complex, although failure of the important mechanical bridge 
provided by DGC has been proposed as the main cause for DMD (Brooks, 1998). 
1.2.2.3 Studies in mdx mouse 
The first animal model for human DMD was the mdx mutant mouse identified in the 1980s 
(Bulfield et al., 1984; Dangain and Vrbova, 1984; Tanabe et al., 1986). These mice carry a 
nonsense mutation in exon 23 of the dystrophin gene. The symptoms are also X-chromosome 
linked with similar features to human patients, but much milder. Unlike the severe disease in 
DMD patients, the mdx mice are comparable healthy, viable and fertile. The relative mild 
phenotype is probably due to compensation from utrophin (Matsumura et al., 1992) and a 
generally higher regenerative capacity in the Mus species (Megeney et al., 1996). 
The structural alterations in mdx mouse muscles include fiber destruction, followed by 
regeneration processes. The muscle weakness and impairment of force generation was 
minimal (Tanabe et al., 1986). The severity of the phenotype also tends to vary with age of 
the animals (Coulton et al., 1988a; Coulton et al., 1988b; Williams et al., 1993). The mdx 
muscles have high susceptibility to contraction-induced injuries, possibly reflecting that 
dystrophin plays a protective role under mechanical stress (Dellorusso et al., 2001; Petrof et 
al., 1993). 
1.2.2.4 Zebrafish Sapje mutant 
The zebrafish dmd gene for dystrophin is located on chromosome 1, and it is an ortholog of 
the human dystrophin DMD gene. The dystrophin protein is fairly conserved, the structure of 
the key protein domains in the two species have strong similarities. The zebrafish Sapje 
mutant was first characterized in 2003 (Bassett et al., 2003). Similar to the mdx mice, the 
Sapje zebrafish also carries a point nonsense mutation in the dystrophin gene causing 
complete loss of functional dystrophin protein. The phenotype of zebrafish Sapje/DMD 
mutant is much more severe than in the mdx mice; the disease associated defects starts to 
reveal at 3 days post fertilization (dpf) in the larvae, and develop until 14-21 dpf when the 
mutant larvae die prematurely. It has been shown that the morphological alterations are 
severe. The cell membrane is often compromised in the mutant larvae, as illustrated by a 
microscopy picture of Evans Blue dye injected larvae from our laboratory (Figure 2) 
accompanied with muscle degeneration and regeneration processes. The pathological 
alterations mimic the structural phenotype observed in human DMD (Bassett and Currie, 
2004; Berger et al., 2010), however, the defects in contractile performance of this model were 
not known. 
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Figure 2. Evans blue dye accumulation in 4 dpf zebrafish larval muscles, indicating cell membrane 
ruptures (arrows) in the Sapje (Sap) mutant in contrast to the normal siblings (Sib), (Li, M. & Arner, 
A. unpublished)  
1.2.3 Merosin-deficient congenital muscular dystrophy (MDC1A) 
Merosin-deficient congenital muscular dystrophy (MDC1A) belongs to a heterogeneous 
group of congenital muscular dystrophies (CMD). The incidence of CMD is very low with 
geographic variations, and is estimated between 0.89-4.7/10 000 (Kirschner, 2013). The most 
frequent subtype is the collagen VI-related disorders or dystroglycanopathy. About ~10% of 
the CMD cases is MDC1A. The disease onset is early at birth or infancy, and progressively 
causing severe muscle weakness with delayed motor development, also spreading to other 
organs including heart and lung. The patients are usually never able to walk, and death occurs 
between 10-30 years of age due to cardiac or respiratory failure (Iannaccone and Castro, 
2013). Currently, there is no curative treatment for this disease, and standard therapy is 
specifically targeting each individual symptom. To improve the quality of life in general, 
multidisciplinary care is considered, including physiotherapy, physical training as well as 
orthopedic surgeries. The MDC1A, also called LAMA2-related congenital myopathy, is 
primarily caused by the completely loss of normal laminin-α2 chain (merosin) due to 
mutations in the LAMA2 gene. The association between autosomal recessive mutations in 
LAMA2 and MDC1A was first reported in 1995 (Helbling-Leclerc et al., 1995).  
Animal models for studying MDC1A are mostly based on mutant (dy/dy, dy2J/dy2J) or 
knockout (dyW/dyW, dy3K/dy3K) mouse strains, which have varied phenotype with different 
genetic defects and protein contents (Gawlik and Durbeej, 2011). Nevertheless, many studies 
indicate that the most common pathogenesis of the disease lies in the structural integrity 
provided by laminin-α2 chain between the cytoskeleton and the extracellular matrix (Brooks, 
1998; Han et al., 2009; Petrof et al., 1993), although the exact role of mechanical contraction 
or intracellular laminin-α2 signaling in the disease development remains unclear. The 
zebrafish MDC1A model (Candyfloss mutant) with a complete LAMA2 deficiency was first 
presented in 2007 (Hall et al., 2007). These mutants revealed a severe phenotype affecting the 
muscle structure, movement as well as the animal life span. In the affected muscle regions, 
the muscle fibers appeared to detach from the myotendinous junctions with extensive 
degeneration and fibrosis. Inflammatory responses also occur. However, sarcolemmal rupture 
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was not primarily observed in this zebrafish model (Hall et al., 2007). The underlying 
mechanism and the precise role of mechanical stress in the disease development remain 
unresolved. Functional characterization is required to fully understand the Candyfloss mutant 
and to further explore the pathological mechanism in this model.  
1.2.4 Myosin binding protein C (MyBPC) and related myopathies 
Myosin binding protein C is a sarcomeric protein located at the M-zone of the striated muscle 
sarcomere. There are three types of this protein, cardiac, skeletal slow and skeletal fast. The 
cardiac type (MyBPC-3) is the most investigated. This work was initiated after the 
establishment of a causal relationship between mutations in this gene and human familiar 
cardiomyopathy (Watkins et al., 1995). The MyBPC-3 protein has 11 domains (C0-C10), 
where the N-terminus and C-terminus interacts with thin and thick filament/titin respectively 
(Winegrad, 1999). Phosphorylation/dephosphorylation of this protein is found to play an 
important regulatory role in positioning the myosin-head and affecting the cross-bridge 
kinetics as well as Ca2+ sensitivity (Harris et al., 2004; Kulikovskaya et al., 2003; Kunst et al., 
2000; Weisberg and Winegrad, 1996).  The structural tethering effect of MyBPC-3 was also 
reported in knockout mouse studies (Korte et al., 2003; Stelzer et al., 2006). Compared to the 
cardiac MyBPC-3, the skeletal types (MyBPC-1 and MyBPC-2) are less understood. 
Structurally, the key domains of three isoforms are fairly conserved, and it has been shown 
that the skeletal MyBPC binds to the sarcomere in a similar manner as the cardiac type, 
although the N-terminal C0 domain and several phosphorylation sites are absent (Luther et 
al., 2008; Oakley et al., 2004). Recently, mutations on MyBPC-1 gene have been associated 
with human distal athrogryposis type 1 myopathy (Gurnett et al., 2010) and congenital 
contractural syndrome type 4 (Markus et al., 2012), showing that the slow type of this protein 
is important in the skeletal muscle context.  
The function of the skeletal form of MyBPC was examined in early work by Moss and 
colleagues (Hofmann et al., 1991a; Hofmann et al., 1991b). They used an extraction 
reconstitution strategy in skinned skeletal muscle fibers and showed that extraction of 
MyBPC caused an increase in maximal shortening velocity. It was suggested that the protein 
affected interaction between actin and myosin and thereby the filament sliding, Consistent 
with this model, knock out of the cardiac form in mice resulted in an increase in shortening 
velocity of cardiac muscle fibers (Harris et al., 2004; Kunst et al., 2000). To our knowledge, 
in vivo studies, where MyBPC have been removed in intact skeletal muscle are not available 
and no disease has been associated with alterations in the fast skeletal MyBPC-2. 
1.3 ZEBRAFISH (DANIO RERIO) 
1.3.1 Zebrafish, a model organism  
The zebrafish is an emerging animal model for biomedical research. The rapid development, 
the optical transparency of embryos, the large number of off-springs, the less problematical 
ethical constrains and low economical costs of this species makes it advantageous as a model 
organisms (Ablain and Zon, 2013; Dooley and Zon, 2000). The animal offers powerful 
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possibilities to study the vertebrate gene function since genetic manipulations, with 
knockdown or over-expression, can be performed and mutagenesis screening and transgenic 
lines are accessible (Lieschke and Currie, 2007). Zebrafish have 25 chromosomes, the whole 
genome size is about half of that in humans (15 billions vs. 30 billions of base-pairs). Recent 
genome sequencing has shown that ~26,000 protein coding genes exist in zebrafish, and they 
share large conservative features with the mammalian genome. Specifically, ~70% of human 
genes have corresponding orthologs in zebrafish (Howe et al., 2013).  
1.3.2 Skeletal muscles in the zebrafish  
Skeletal muscles constitute a major part of the zebrafish trunk and tail, and are functional 
supporting animal motions already from ~ 18 hours post fertilization (hpf). The slow and fast 
muscle fibers are found in the trunk at separate locations; the slow fibers are found in the 
peripheral layer under the skin while the fast are more internal and more abundant (Devoto et 
al., 1996). General muscle cell structure, sarcomeres and anaerobic/aerobic functions are 
conserved in zebrafish muscles. But unlike the mammals, the zebrafish retains the structure of 
somites where the skeletal muscle fibers are arranged in parallel between two adjacent 
myosepta (arrows in Figure 3). 
 
 
 
 
 
 
 
Figure 3. Schematic view of general muscle fiber organization and composition in zebrafish larval 
muscles (4 dpf). The slow fibers (indicated as red) form one single cell layer underneath skin, the 
majority of the trunk muscles are the fast type (white). Left: longitudinal section through the larval 
trunk region, muscle fibers attach between two adjacent myosepta. Right: transverse section at mid-
trunk region.  
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1.3.3 Modeling muscle disease in zebrafish 
For zebrafish, significant research interest has focused on the embryology and developmental 
biology due the “ex-uterus” development and optical transparency. As the knowledge and 
experience on this species is expanding, zebrafish have also been used to model human 
diseases. In 2003, the first zebrafish model for muscle disease, the Sapje mutant, was 
discovered and characterized (Bassett et al., 2003). In the field of muscle disease, several 
approaches have been applied in zebrafish to model human disorders, including 
forward/reverse genetic studies and transient genetic modifications (Wood and Currie, 2014). 
1.3.3.1 Mutagenesis screening and transgenic strains 
One of the oldest strategies, chemical mutagenesis by N-ethyl-N-nitrosourea (ENU), is 
powerful to introduce mutations on a large genome scale (Justice et al., 1997). Following the 
success in other organisms (mouse, fly, worms), ENU screening was established in zebrafish 
to study the forward genetics since the 1990s (Solnica-Krezel et al., 1994). However, the 
effect of ENU is highly nonspecific and random, the phenotypic screening requires large-
scale tests. Furthermore, the subsequent genetic linkage mapping is needed to locate the 
mutation on the chromosome. Therefore, this method is suitable for large research centers 
with joint-efforts on maintaining of zebrafish lines, phenotyping and genetic mapping. Up to 
now, the zebrafish mutant lines with various genetic defects have been established in e.g. 
Tübingen, Germany and Boston, USA (Knapik, 2000). For several mutants, the genetic 
lesions have also been identified, e.g. Sapje (dmd), Candyfloss (lama2), Softy (lamb2). 
Transgenic zebrafish strains for human disorders have also been created using recombinases 
(Dong and Stuart, 2004). However, they are less studied due to the limited techniques for 
targeting the zebrafish embryonic cells (Fan et al., 2006). Recently, novel techniques have 
been developed to generate stable mutant and knockout lines, e.g., zinc-finger nucleases, 
transcription activator-like effector hybrid nucleases (TALENs) and clustered regularly inter-
spaced short palindromic repeats (CRISPR’s)/cas9 system (Doyon et al., 2008; Huang et al., 
2011; Hwang et al., 2013).  
1.3.3.2 Morpholino antisense-oligonucleotides (MOs) 
“Morpholinos” are chemically modified oligonucleotide analogs. They inhibit the expression 
of selected genes through a base-pairing mechanism (Heasman, 2002). The inhibitory effects 
can target the splicing of premature RNAs (splicing blocking MOs) or the initiation of the 
protein translation (translational blocking MOs). Compared to small interfering RNAs 
(siRNA), the structural modifications of MOs enables a higher solubility, higher affinity for 
the target RNA sequence, longer stability in biological systems with significantly lower off-
target effects (Summerton, 2007). Since the information on genetic sequencing is available in 
zebrafish, the design of MOs is fairly simple and available to users; different designs of MOs 
for one gene-of-interest could be obtained at low cost. For the knockdown in zebrafish, 
morpholinos are injected into the yolk of embryos at the 1-2 cell stage, and then taken-up into 
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the cells by the yolk stream. The effects of MOs are non-stable, transient during the larval 
stage, although the MOs are persistent and resistant to degradation in vivo. This approach has 
been popular in zebrafish field owing to the low cost and high efficiency.  
There are, however, also some concerns with regard to the authenticity of the phenotype and 
the proper use of control MOs. The off-target effects are theoretically minimal in the use of 
MOs; however, a dose-associated toxicity and non-specific phenotype have been shown in 
some cases (Bill et al., 2009). Moreover, in some studies, the use of mismatched control MO, 
where several bases of the effect MO are mismatches, often interfere with endogenous RNA. 
The most commonly used control MO is the standard MO, which targets a human beta-globin 
intron mutation (designed by Gene Tools LLC). It has been shown to cause negligible 
phenotype effects in most test systems and can serve as a negative control. The accuracy and 
the specificity of MOs thus have to be validated with caution, it has been proposed that the 
phenotype caused by MOs should be verified in both blocking strategies (splicing blocking 
and translation/ATG blocking of mRNA). Phenotypic rescue of the corresponding mRNA 
should also be considered (Eisen and Smith, 2008). 
1.3.3.3  Structural and functional evaluation of zebrafish skeletal muscles 
The structural examination of zebrafish larval muscles has been well established. In early 
muscle developmental studies, several basic techniques, including tissue sectioning, whole-
mount preparations, immunohistochemistry, hematoxylin and eosin stain, in situ 
hybridization, etc., have been well documented. In the first zebrafish model for muscle 
disorder (Bassett et al., 2003), birefringence microscopy was also applied and revealed 
characteristic features of dystrophic muscle fibers in the larval trunk. The measurement of 
muscle damage by birefringence quantification was further established (Berger et al., 2012) 
and also applied in other zebrafish mutants with muscle dystrophies, e.g., Candyfloss (Sztal et 
al., 2012). Specifically, Evans blue dye is also a useful tool to examine the sarcolemmal 
integrity, and revealed compromised cell membrane in zebrafish Sapje mutant (cf. Figure 2). 
Given the optic advantages of early zebrafish larvae, microscopic investigation has been an 
important approach. Ultra-structural examination was also available using electron 
microscopy. In addition, a classic structural evaluation method in muscle, small angle X-ray 
diffraction, has been applied in the larval muscles (Dou et al., 2008). 
Compared to the structural investigations in zebrafish larvae, the functional characterization 
of muscle tissue was less established. The early studies have been focused on the swimming 
property and behavioral pattern of the larvae. The functional impairment observed in these 
studies could reflect more the general locomotor defects, but remain less specific for the 
muscle function per se (Saint-Amant and Drapeau, 1998). Moreover, in most cases, the subtle 
changes in the muscle force could be undetectable due to the limited resolutions of the assay. 
The first direct mechanical measurement of muscle force was reported in 2008 (Dou et al., 
2008), where the active contraction could be recorded and length-tension relationship was 
characterized on the larval muscles. These functional techniques, measuring active force, are 
important for translation to the normal and diseased human muscle. More advanced 
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mechanical examinations on the contractile or elastic properties of the muscles can give 
further mechanistic information importance for understanding the function of normal and 
mutated muscle proteins. 
1.3.4 Therapeutic screening in zebrafish larvae 
As discussed above, zebrafish develop rapidly and reproduce in large quantity; the small size 
and independency on cardiovascular or food support during early stage make them popular in 
high throughput screens. They have been used in multi-well system for chemical screening 
since 2000 (Peterson et al., 2000). The approach was simply carried out by adding the 
compound into the fish water and evaluating the phenotypes. For the zebrafish mutants with 
muscle disorders, the same approach could also be applied for therapeutic screening and 
evaluation of small molecules, where the effects on structural and functional improvement or 
toxicity could be assessed. It has been reported that therapeutic candidates for human DMD 
were tested in zebrafish Sapje mutant larvae, the phenotypic improvement was recorded and 
structural restorations were also evaluated (Kawahara et al., 2011). In addition to small 
molecule screening, other therapeutic strategy e.g. genetic modification with exon-skipping, 
has been tested using the zebrafish Sapje DMD model (Berger et al., 2011). So far most 
studies have focused in effects on structure. It should be noted that a main therapeutic goal in 
muscle disease is to improve muscle function in the patient, and it is therefore relevant to 
include analysis on the therapy effects on muscle force.  
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2 AIM 
This thesis is aimed to answer the following research questions: 
• Can physiological studies of zebrafish larvae be used for analysis of protein function 
in muscle? 
• Can zebrafish models of muscle disease be used to explore pathological mechanisms 
relevant for the situation in humans and to examine effects of novel therapies? 
• What are the structural and mechanical consequences of partial desmin removal in the 
zebrafish skeletal muscles? 
• Do zebrafish models lacking dystrophin or laminin α2-chain mimick clinical 
observations in Duchenne (DMD) and Congenital (CMD) Muscle Dystrophies? 
• What are the effects and dose dependency of Ataluren, a read-through compound, on 
muscle function in the Sapje/DMD model? 
• Can the muscle dystrophic development be influenced by muscle immobilization? 
• What are the roles of Myosin Binding Protein C (MyBPC) in skeletal muscle 
development and function?  
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3 MATERIAL AND METHODS  
3.1   Animals 
The papers included in the thesis are based on studies of zebrafish models, either after gene 
knockdown with morpholino antisense oligonucleotides (cf. section 3.3) or using different 
mutated strains. The zebrafish wild-type strains (AB and TU, Papers I and IV), used in 
morpholino knockdown studies, were regular breeds at the CMB zebrafish facility, KI. The 
dmd/sapta222a (Sapje) mutant strain (Paper II and III) was imported from Tübingen, 
Germany and the cafteg15a (Candyfloss) mutant strain (Paper III) was a gift from Monash 
University, Australia (Dr. P. Currie). For the mutants, the heterozygous animals carry a single 
missense mutation in the dystrophin (Sapje strain; Basset et al., 2003) or the laminin α2 
(Candyfloss strain; Hall et al., 2007) gene on one allele. They have normal protein expression 
with healthy phenotype and normal life span; whereas the homozygote animals lack the 
corresponding protein and exhibit defects in musculature. The larvae were used within 6 days 
post fertilization (dpf). If not euthanized, the homozygous animals of each strain will die 
early, from about 10 dpf, most likely due to impaired food intake. The zebrafish larvae are 
easily anesthetized and immobilized using Tricaine (MS-222), and higher doses of the 
compound were used to euthanize the animals (Westerfield, 2000). 
3.2   Genotyping (Papers II and III) 
The homozygous mutant Sapje and Candyfloss strains were easily identified with 
birefringence (Section 3.5), but genotyping was also performed to identify heterozygous adult 
breeding pairs and homozygous larvae following treatment, when they did not exhibit 
structural changes (Paper III). Genomic DNA was exacted from the tip of tail-fin tissue 
(adult fish) or from the whole body (early larvae). The identification of the mutant allele was 
achieved using derived cleaved amplified polymorphic sequence (dCAPS) analysis (Neff et 
al., 1998). In principle, the gene fragment harboring the point mutation was flanked and 
amplified using standard three-step PCR, using primers resulting in a restriction site in the 
mutated samples. The PCR products were subsequently digested with the restriction enzyme, 
with a successful cut of the fragment from the mutant allele at the site of the point mutation. 
The corresponding PCR products from wild type allele remained intact after the digestion. 
Thus, the wild type (+/+), heterozygous (+/-) and homozygous (-/-) animals could be 
identified from the number of bands after restriction digestion. The primers and restriction 
enzymes used for each strain were described previously (Sztal et al., 2012). 
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 Figure 4: Genotyping of zebrafish mutants. 
Following PCR amplification of genomic DNA, 
using primers flanking the region harboring the 
point mutation, the products were then digested 
with restriction enzyme that cuts at the mutation 
site, and separated on agarose gel. The 
corresponding bands from wild type (+/+), 
heterozygous (+/-) and homozygous (-/-) Sapje 
(Sap) and Candyfloss (Caf) could be identified.
3.3   Knockdown approach (Papers I and IV) 
Morpholino antisense oligonucleotides (MO) are designed to target the splicing site (intron-
exon or exon-intron junction) on the premature mRNA or the ATG site of mRNA, resulting 
in mis-spliced mRNA (splice blocking) or un-translated protein (translation blocking), 
respectively (Bill et al., 2009). The MOs were designed based on the DNA sequences, 
synthesized and obtained from Gene Tools LLC (Philomath, OR, USA). We used this 
technique to knock down desmin (Paper I) and myosin binding protein C (Paper IV). Since 
we identified several isoforms several MOs were used, either alone or in combination. The 
animals with gene/protein knockdown are denoted morphants. The morpholino 
oligonucleotides are small in size (25-bases), and can easily be delivered into the embryos by 
yolk-injection at the 1-2 cell stage. The amount of MO injected per larva was about 5 nL (~4 
ng oligonucleotide). A standard control MO (5'-CCT CTT ACC TCA GTT ACA ATT TAT 
A 3') was used in both Paper I and IV. This sequence is supposed to have no target or 
biological activity in the zebrafish larvae (Gene Tools LLC), and was used to exclude 
unspecific effects of oligonucleotide injection. We did not in our studies observe any 
differences between wild type and the control MO injected larvae in the mechanical and 
structural experiments. The specific knockdown effects of designed morpholino 
oligonucleotides in the larvae was detected at the protein level using Western blotting, silver 
stained gels or immunohistochemistry; and, for the splice blocking MOs, also at the mRNA 
level using PCR.  
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 Figure 5: Schematic illustration of the early development of organ functions in zebrafish larvae and 
of the experiments using morpholino antisense oligonucleotide (MO) injection. 
3.4   General morphology and immunohistochemistry 
In all papers we examined the effects of MO injection or mutations on the larval morphology 
and muscle structure. The 4-6 dpf zebrafish larvae are small and transparent to light, which 
make it possible to examine the morphology of the whole body using microscopy. A general 
overview of the larvae (e.g. to identify large anatomical changes and measure length and 
width) was obtained using standard light microscopy of anesthetized or euthanized larvae. 
The birefringence technique used on living larvae is described below in Section 3.5. More 
specific information was obtained using fixed samples. The larvae were euthanized with 
Tricaine and then fixed in 4 % paraformaldehyde (PFA) at 4 ºC overnight at defined degrees 
of stretch. For general examination of the sarcomeric structure, whole-mount preparations of 
larvae were stained with Rhodamine phalloidin, which stains F-actin filaments. This enabled 
studies of muscle fiber orientation and measurements of sarcomere length. In Paper II, the 
fixed preparations were stained with anti-dystrophin primary antibody (DSHB) and Alexa 
Fluor-488-conjugated secondary antibody to detect the protein content and location. To 
determine the relative content of fast and slow muscle myosins, the larvae were embedded in 
freeze section medium (O.C.T.), sectioned transversely (10 µm), fixed in acetone, and stained 
with S58 (mouse anti slow myosin) and F59 (mouse anti fast myosin) primary antibody and 
Alexa488 secondary antibodies. The collagen content was examined in cross-sections using 
Sirius Red staining. The images were recorded and analyzed using a confocal microscopy 
system (LSM 510; Carl Zeiss, Germany). 
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3.5   Birefringence assays (Papers II and III) 
Skeletal muscle is birefringent, due to the optical properties of the sarcomere affecting the 
polarization of transmitted light. When the larval muscle is illuminated with polarized light 
and observed through a second polarizer at 90o angle, the background is dark and bright/light 
areas appear where the muscle is birefringent (i.e. with regular sarcomeric structure). This 
property has been explored to examine dystrophic changes in muscle structure of the 
zebrafish larvae (Berger et al., 2012). It has been shown that in zebrafish muscular dystrophy 
larvae (Sapje and Candyfloss), the affected muscle cells undergo necrosis/degeneration, 
indicated as dark patchy areas under birefringence microscopy. The homozygous mutants 
start to reveal these birefringence defects at 3 dpf, and allow the differentiation from their 
normal siblings. The polarized light intensity was quantified in Paper III as a measure of the 
muscle damage. 
3.6   Small angle X-ray diffraction (Papers I and IV) 
The regular arrangement of sarcomeres and contractile filaments give rise to light scattering, 
interference and diffraction. The length of the sarcomeres (in the µm dimension) can be 
estimated using light diffraction from a HeNe laser (wavelength 632 .8 nm). However, for 
resolution of interfilament distances (20-50 nm) lower wavelength light has to be used (about 
1 Å=0.1 nm). In principle the muscle is illuminated by focused X-ray light. Scattering and 
interference generates a diffraction pattern where periodic structures (e.g. distances between 
filaments) create reflections. The distance between these reflections is inversely related to the 
spacing of the diffracting structures. Since the distance between filaments is large compared 
to that in e.g. protein crystals the scattering angle is small requiring a comparatively long 
camera length (i.e. distance between sample and detector) to be resolved (i.e. Small Angle X-
ray Scattering, SAXS). For example the spacing of the 1.1 and 1.0 reflections is reflecting 
lateral distances between the contractile actin and myosin filaments (Millman, 1998; Figure 
6). The intense focused and high energy light with a broad wavelength spectrum generated by 
accelerated charged particles in synchrotron light facilities has been used in muscle research 
(Wray and Holmes, 1981). The experiments were done at the A2 beamline at the Hamburger 
Synchrotron- Strahlungslabor (HASYLAB)/Deutsches Elektronen-Synchrotron (DESY) 
synchrotron facility in Hamburg, Germany, and the I911-SAXS beamline at the MAX II ring 
of the MAX IV Laboratory in Lund, Sweden. In these beamlines, the X-ray beam is focused 
on the larvae (beamsize at Hamburg: ~ 300 x 2000 µm; Lund: 100 x 100 µm). The 2-
dimensional pattern of diffracted light is recorded using sensitive detectors (Mar CCD or 
Pilatus) at a distance of 3-4 meter. The position of the reflections was determined and the 
spacing between filaments could be calculated knowing wavelength and camera length or 
from calibrations using samples with known spacing (collagen or Silver behenate).  
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Figure 6. Left: transverse view of thick and thin filament lattice. Right: equatorial reflections in X-ray 
diffraction of skeletal muscles. Modified from Millman (1998). 
Our group has previously demonstrated that X-ray diffraction patterns can be recorded from 
single zebrafish larvae (Dou et al., 2008) and the SAXS technique was used in Paper I and 
IV to determine the filament distances after knockdown of desmin and myosin binding 
protein C. The larval preparations were mounted horizontally in a Kapton-window cuvette 
with MOPS buffered physiological solution at room temperature. We exposed the muscles 
during 1-10 s and recorded the pattern. In these studies we focused on the equatorial patterns 
reflecting filament distances. 
In Paper I, the larval preparations examined at varied stretch (i.e. sarcomere length) which 
enables estimation of sarcomere volume (Millman, 1998). We related the length changes in 
X-ray experiments to the mechanical data using the extent of stretch (muscle length relative 
to slack) or using the sarcomere length (determined with laser diffraction). To examine the 
influence of filament spacing in relation to active tension the osmolarity of the bathing 
solution was varied. The muscles were swelled (low NaCl) or compressed by adding sucrose 
in MOPS buffered solution. The structural data at different osmolarities was correlated with 
mechanical experiments as described below. 
During contraction, myosin heads are considered to move out and attach to actin affecting the 
intensity of the equatorial 1.1 and 1.0 reflections (Haselgrove and Huxley, 1973). Outward 
movement towards actin weakens the 1.0 intensity and increases the 1.1 intensity. Since the 
SAXS studies can be performed in non-fixed, non-stained samples it is possible to record 
cross-bridge movement during contraction. In Paper IV, we established a procedure for the 
zebrafish larvae where the muscle was repeatedly (15 times) stimulated with short (200 ms) 
tetanic contractions. The detector was gated to be open in the relaxed state or during 
contraction, thus enabling us to record relaxed and contracted patterns. We also opened the 
X-ray shutter only when recording to minimize muscle exposure to the X-rays. To obtain a 
situation with maximal attachment of myosin, we recorded patterns in rigor conditions 
induced by incubation with 2 mM NaCN. 
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3.7   Protein expression analysis 
To examine the knockdown effect of translation blocking MOs, as well as the splicing MOs 
on the protein level, protein expression of the control and MOs injected larvae was analyzed. 
Proteins were purified from early larval trunk muscles. The head, yolk, gut and other organs 
were removed as much as possible, to exclude possible contaminations from non-muscle 
tissue. The tissues were homogenized in an SDS containing solution (composition see Paper 
I), centrifuged and loaded on the gels.  
Silver staining 
In Paper IV, we estimated the content of Myosin Binding protein C using silver stained gels, 
since we could not obtain an antibody that could be used. The protein extracts were loaded 
and separated on 7% polyacrylamide gels. Extracts from one single larva were loaded on 
each lane. After the electrophoresis, the gel was washed briefly in water, subsequently stained 
and the proteins visualized using a SilverQuest™ Silver Staining Kit (Life technology). The 
intensity of the stained proteins bands was estimated using densitometry (Bio-Rad system, 
Bio-Rad Laboratories). 
Western blotting 
Extracts from 5-15 larvae were loaded on each lane of 10% polyacrylamide gels. Protein 
bands were transferred to nitrocellulose membranes and incubated with primary antibody 
(rabbit polyclonal anti-desmin in Paper I and mouse anti-dystrophin in Paper III). Anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody was used in both studies as a 
control. ECL Western Blotting Detection Reagents, photographic film (Fuji), and optical 
detection (Bio-Rad system) were used to quantify the intensity of the protein bands.  
3.8   Behavioral analysis 
Optical analysis of larval swimming can be used as a semi-quantitative method to identify 
major motility problems (Granato et al., 1996). The zebrafish larvae were examined using an 
automated behavioral analysis system, ZebraLab V3 (ViewPoint Life Sciences Inc) at 4-6 
dpf. The larvae were morphants, pre-injected with morpholinos (Paper I) or mutants, pre-
selected under birefringence (Paper III). They were transferred to 24-well plate in E3 
medium, 1 larva per well, an allowed to acclimatize for 30 min at 22 oC. The swimming 
pattern then was recorded for 1-2 min. Large and small movements of each larva were 
tracked and analyzed, the parameters included in the studies were: duration, distance covered 
and moving speed of each movement type. 
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Figure 7. Representative recordings of 4 dpf TU 
larvae during 2 min swimming behavior analysis 
on 24-well plate, one larva per each well. Red 
traces indicate large movements. 
 
 
 
3.9   Pharmacological treatment 
Zebrafish larvae enable comparative high-throughput studies of the effects of 
pharmacological intervention. Using our mechanical approach, we provide a functional 
readout. The zebrafish larvae start to hatch from the chorion at 3 dpf and live on the yolk as 
nutrition source until ~ 6 dpf. They absorb oxygen and other chemicals (e.g. electrolytes and 
drugs) from the bathing E3 medium through skin or digestive track. Thus, the 
pharmacological treatments of the larvae can be applied directly to the bathing medium at the 
desired concentration. To ensure a proper absorption, the larvae were manually dechorionated 
before the treatment, and solutions were renewed every day. The animals were kept in 24-
well plate during the treatment, one larva per well; the survival/mortality rate and touch-
response were monitored through the treatment. The experiments were terminated and the 
muscle structure and/or function were analyzed after 2-4 days. For both Ataluren (Paper II, 
Section 3.9.1) and BTS (Paper III, Section 3.9.2) treatments, 0.1% DMSO was applied as a 
solvent control.  
3.10   Ataluren treatment (Paper II) 
In Paper II, we examined the functional and structural effects of a novel compound Ataluren 
(PTC 124) causing read-through of pre mature stop codon (Welch et al., 2007), in the Sapje 
dystrophy model. The compound was purchased from Selleck Chemicals (Houston, TX, 
USA), dissolved in DMSO to obtain two stock concentrations (5 mM and 35 mM), and then 
added to the E3 medium to reach the final dose (0, 0.1, 0.5, 1, 5 and 35 µM). The treatment 
was initiated at 3 dpf, when the mutant larvae and siblings could be identified with 
birefringence microscopy. After the functional and structural analyses at 5 dpf, the larval 
preparations were kept and genotyped to confirm their genetic identities.  
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Figure 8: Schematic view of the experimental plan for Ataluren treatment. 
3.11   BTS treatment (Paper III) 
To examine the effect of immobilization on structural and mechanical dysfunction in Sapje 
and Candyfloss dystrophic larvae we applied N-benzyl-p-toluene sulphonamide (BTS), which 
is a compound that inhibits actin-activated myosin ATPase (Cheung et al., 2002) and 
contraction of mammalian (Pinniger et al., 2005) and zebrafish larval muscle (Dou et al., 
2008). Since hatching involves active muscle movement the BTS treatment was initiated 
early at 18 hpf, when the homozygous mutants and siblings have the same phenotype. The 
larvae were dechorionated and then treated with 50 µM BTS from 18 hpf to 4 dpf, a dose 
giving complete inhibition in mouse EDL (Fredsted et al., 2007), and then analyzed after 1 hr 
(at 4 dpf) and 1 day (5 dpf) washout in E3 medium, as illustrated in Figure 9 below. Since the 
treatment was initiated before the homozygous animals could be indentified, each sample was 
genotyped after analysis.  
 
Figure 9. Schematic view of the experimental plan for larval immobilization using BTS. 
3.12   Mechanical analysis 
We analyzed muscle contraction as a key functional readout in the studies of morphants 
(Paper I and IV), in mutated strains and after treatment (Paper II and III). We used single 
twitch stimulation and determined maximal active force at optimal stretch (Section 3.12.1) In 
Paper I we also used tetanic stimulation and applied a stretch protocol to examine effects of 
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eccentric contractions (Section 3.12.2) The larvae were analyzed at 4-6 dpf and euthanized 
with Tricaine. Aluminum clips were wrapped around the larval head and the tip of the tail, 
and the preparation mounted horizontally in a cuvette between a force transducer attached to 
a micrometer screw and a hook attached to a motor enabling rapid length changes. The 
cuvette was perfused with a Krebs-Ringer bicarbonate buffered solution gassed with 95%/5% 
O2/CO2, or with MOPS buffered solution (composition of solutions is given in Papers I and 
II) at room temperature (22 oC). The muscles were stimulated via two platinum electrodes 
placed on the sides of the cuvette. 
 
Figure 10: Mounting of larval preparation and force recording on 4-6 dpf larvae. Upper panels: 
original recording of force traces from a single twitch and high-frequency tetanus contraction. Lower: 
schematic view of the mounting strategy. 
3.12.1   Single-twitch contractions and length-force relationships 
It has previously been found that single twitch stimulation gives near maximal force in 
zebrafish larval muscle (Dou et al., 2008) and we therefore used this mode of stimulation in 
our analysis of contractile function. The larval preparations were stimulated with 0.5 ms 
electrical pulses (supramaximal voltage) at 2-min intervals. An initial contraction was 
recorded at slack length, and then the preparation length was increased step-wise between the 
contractions via the micrometer screw, until a length above the maximal for active force, to 
ensure that the optimal length (Lopt) for maximal active force was determined. At each step, 
length and the active and passive force were recorded. Force signals were recorded and 
analyzed using LabChart® (ADInstruments Ltd, Oxford, UK). The length-force relationship 
was determined by plotting the relative length of the preparation against the relative force 
generated at each length. 
3.12.2   Tetanic stimulation and eccentric contraction (Paper I) 
For tetanic contractions, larval muscles were mounted at Lopt, stimulated at 200 Hz for 200 
ms, with 5 min intervals between the stimulations. The contractions fused at 60 ms after onset 
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of stimulation and exhibited a plateau during the tetanus. To examine stretch-induced damage 
on the larvae, a length ramp (10% stretch, at a rate of 2 Lopt/s) was imposed on top of the 
tetanus after 60 ms using the length motor. The preparations were kept at the stretched length 
for 200 ms and returned to Lopt in the relaxed state after the contractions. The protocol is 
illustrated in Fig. 5 of Paper I. The eccentric contractions were applied for 10 times, the 
tetanus force during the first contraction, was used to normalize subsequent force responses. 
Control responses were recorded on muscle repeatedly activated.  
3.12.3   Force-velocity relationship (Paper IV) 
The force-velocity relationships of 4-5 dpf larvae were determined at lowered temperature 
(15 oC). A velocity ramp protocol was applied during single twitch contractions.  To ensure a 
steady velocity, the shortening ramp was initiated 50 ms prior to the stimulation, and also the 
preparations were pre-stretched so that the actual length at peak of the twitch was the same. A 
series of different ramp speeds was applied at 2-min intervals, and the corresponding force 
was recorded. The isometric tension was also determined between each iso-velocity 
contraction. The technique is further discussed in relation to the results in Section 4.4.4. 
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4 RESULTS AND DISCUSSION 
In the papers included in the thesis, we have focused on the contractile and structural 
functions of four key muscle proteins, Desmin, Dystrophin, Laminin and skeletal Myosin 
Binding Protein C (MyBPC). They locate at different sites in the muscle cells, and in many 
aspects, their functions are unknown or under-explored in vivo. They are all involved in 
human muscle disease. We applied and developed techniques for functional analysis in 
zebrafish larval muscle and examined the normal protein functions and their potential roles in 
disease, using knockdown strategies and mutated strains. The figure below illustrates the 
location of the proteins examined in the included papers.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 11. Schematic illustration of cytoskeletal proteins examined in the papers of the thesis.  
4.1 DESMIN - DESMINOPATHY 
Desmin is a major component of the intermediate filaments in muscle (Lazarides, 1980). Its 
structural role in anchoring the cellular components and maintaining the sarcomere 
arrangements in skeletal muscle has been well documented (Boriek et al., 2001; Capetanaki 
et al., 1997; Goldfarb et al., 1998). Several forms of human desminopathy caused by 
mutations in the desmin gene exist (Dalakas et al., 2000). As stated in the Introduction 
(Section 1.2.1), human desmin-related myopathies are manifested by loss of functional 
desmin, as well as by the appearance of intracellular protein aggregates. These protein 
deposits were suggested to be toxic (Sugawara et al., 2000). If the deposits are the main cause 
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or consequence of the disease, and whether toxic effects or a lack of functional protein are the 
pathological mechanisms remain open questions. Human desminopathy is a very 
heterogeneous disease and, most likely, the pathological mechanism might vary among 
individual forms. To investigate the exact mechanisms in human desminopathy, knock-out 
mouse models have been developed and extensively studied (Li et al., 1996; Milner et al., 
1996). The links between desmin mutations, aggregates and disease phenotype have been 
investigated in the human studies and some mouse models (Carlsson et al., 2002; Muñoz-
Mármol et al., 1998), showing that mutations in desmin can affect the formation and stability 
of the intermediate filaments, as well as the cellular localization of other cytoskeletal 
proteins. Studies on knockout (DES-/-) mice, where desmin is completely absent, have 
revealed a comparatively mild phenotype with alterations in muscle structure and function, in 
the absence of protein aggregates (Balogh et al., 2005; Sam et al., 2000). However, the 
heterozygous (DES+/-) mice, where desmin content is lower, did not show any disease 
phenotype (Li et al., 1996; Milner et al., 1996). Thus, the primary disease mechanisms in 
humans, where desmin is not completely absent, remain to be determined - whether it is the 
truncated protein aggregates or the lowered desmin that affect the muscle function. It is also 
relevant to mention, in this context, that most experimental models of desminopathy are 
developed in the mouse, and information from other species, perhaps better mimicking some 
aspects of human disease, could be of value. In Paper I, we used a morpholino antisense 
approach to lower desmin content in zebrafish larvae, and found that a partial decrease of 
desmin is sufficient to cause structural and functional damage in muscles. As discussed below 
we propose that this model, with partial desmin knockdown and absence of protein 
aggregates, mimics some aspects of human desminopathy. The desmin knockdown larval 
model also enabled us to explore more basic functions of desmin on the muscle contractile 
apparatus using a combined mechanical and structural approach. 
4.1.1 Desmin knockdown in zebrafish larvae 
Genes in zebrafish are often duplicated. For desmin, both genes (desma and desmb) were 
identified in the zebrafish using the NCBI (National Center for Biotechnology Information, 
USA) database. The desmin protein is fairly conserved when compared to human (71% 
identity of the sequence). In Paper I, we designed primers and demonstrated using RT-PCR 
that both genes were expressed in larval muscles at 4 dpf. Since the mRNAs of both desmin 
genes were present in zebrafish, we used a combination of morpholino antisense 
oligonucleotides (MOs) targeting both of the genes to achieve a significant knockdown. The 
amount of MOs was kept below the amount considered toxic and injection with the standard 
control MO did not have an affect on the measured parameters (e.g. larval body length/width, 
active force). Thus the control MO injected larvae were routinely used as control for 
comparisons with the animals injected with blocking MOs. Further, we used two different 
MO approaches: splicing and translation blocking MOs as discussed previously. The Figure 
12 below shows mRNA expression in zebrafish larvae after injection with control and 
splicing blocking MOs, demonstrating a significant knockdown at the mRNA level by the 
blocking MOs. 
  27 
 
Figure 12. Gel separation of mRNA transcripts 
for desmin (des-a and des-b) in zebrafish larvae 
injected with control and splicing blocking MOs 
targeting each gene respectively. 
It is also important to confirm that injection of blocking MOs is associated with lowering of 
protein content. With Western blotting, we detected a significantly lowered protein content 
by ~ 50% (Fig. 1 in Paper I), for both splicing and translational blocking MOs. Due to the 
nature of MOs and the delivery method used in the larvae (local injection into the yolk, MOs 
are taken-up into cells from yolk), the knockdown effect is transient (days to one week) and it 
is often impossible to achieve a complete knockout.  
We examined the larvae at 4-5 dpf, and the desmin morphants showed a severe muscle 
phenotype. They also had shorter body length, cardiac edema and an impaired swimming 
activity compared to the control group (Table 1, Fig 2. of Paper I). These results show a 
prominent effect of knockdown on the skeletal muscle structure and function. Most likely the 
knockdown also affects cardiac and smooth muscles, since desmin is expressed in all muscle 
types (Lazarides, 1980). Defects in the heart or gut are however less likely to cause any 
secondary effects on the skeletal muscles, since cardiovascular/intestinal functions are not 
essential for zebrafish larvae as the oxygen is diffused through the skin and yolk stream 
supplies the nutrition (Lin, 2012). 
4.1.2 Desmin deficiency results in structural alterations 
We examined the structural effects of desmin knockdown in the zebrafish larvae in more 
detail using confocal microscopy and staining of F-actin with Rhodamine phalloidin. A 
picture is shown in Fig. 2 of Paper I. The desmin morphants had generally thinner and 
disarranged muscle fibers. We observed regions where the anchoring sites of the muscle 
fibers and the myosepta were compromised. No protein aggregates were observed in this 
knockdown model. These results thus show that loss of desmin significantly affects the 
muscle structure with effects on the regular arrangement of fibers and of their attachments 
sites. These results are similar to results from the desmin knockout mouse models (Li et al., 
1997). However, the heterozygous desmin knockout mice do not have a clear pathological 
phenotype although protein content in muscles is lower (Li et al., 1997; Milner et al., 1996). 
Our results thus show that a partial loss of desmin is sufficient to cause structural alterations 
and a myopathy, which could be important for translation to the human desminopathy, where 
desmin is not completely absent.  
Since desmin can be a major component in the lateral anchoring of the sarcomeres, binding 
between the Z-disks and the muscle costameres (Tidball, 1992), we further examined the 
myofilament structure using small angle X-ray scattering, addressing the hypothesis that the 
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desmin intermediate filaments affect the sarcomere structure. We obtained strong equatorial 
signals at the synchrotron facility and estimated the interfilament distances from the 
equatiorial 1.0 and 1.1 reflections. The inner 1.0 reflection was strong and its spacing (d10) 
was primarily used in the analysis (Fig. 3 in Paper I). The d10 spacing was significantly 
wider in the desmin morphants. The difference appeared larger at shorter sarcomere length, 
showing, that when the sarcomeres are shortened the filaments move apart maintaining 
sarcomere volume (Millman, 1998), and that this behavior was altered in the desmin 
morphants. The mechanism for the wider filament spacing in desmin morphants thus seems 
to be related to the lack of lateral links of the sarcomeres and is similar to results from the 
desmin knock-out mouse (Balogh et al., 2005). Thus the desmin intermediate filaments affect 
the lateral compliance and have role in maintaining lattice spacing in the sarcomere. 
As discussed below (Section 4.1.3) the active force was lower. It has been reported that 
moderate changes in fiber width and lateral spacing affect the contractile properties (Edman, 
1999), and we examined if the spacing change in the desmin morphants was large enough to 
affect contraction. In the experiments, we therefore compressed the desmin morphants using 
sucrose in the bathing medium to the widths observed in controls; and expanded the lattice of 
the controls to a level of the morphants and examined contractions as discussed below 
(Section 4.1.3). 
4.1.3 Lowering of desmin content impairs muscle contraction, but prevents 
stretch-induced injury 
In general the zebrafish larvae lave a low maximal active stress (about 20-50 mN/mm2, 
Paper I and Dou et al., 2008), as estimated from muscle cross-sectional area and active force, 
compared to e.g. about 360 mN/mm2 in single muscle fibers frog and mouse (Edman, 2005). 
For each muscle, we confirmed that the measurements were made at optimal stretch and with 
supra-optimal stimulation intensity. The tetanic contractions in the zebrafish are of about the 
same magnitude as the single twitch contractions (cf Dou et al., 2008), which show that we 
cannot obtain higher force with summation. One explanation for this is the very fast muscle 
type. It is likely that the fast zebrafish muscle fibers cannot maintain tension during the 
tetanus and that they fatigue during the sustained contraction and thus to not contribute with 
summation of tension. This is also supported by results showing that a myosin inhibitor 
(BTS) mainly inhibiting fast myosin, primarily attenuating the early phases of contraction 
(Dou et al., 2008). Another important contributing factor can be the predominant fast muscle 
type in the zebrafish (Devoto et al., 1996). A higher cross-bridge cycling of zebrafish muscle 
in general, since higher cycling rates will lead to shorter duty cycles (i.e. the time a cross-
bridge is attached in a force generating state) and that give lower tension (Rome et al., 1999), 
which is also supported by the X-ray data discussed under Section 4.4.3. 
The decrease in desmin content was ~50% in the morphant larvae (Section 4.1.2) and we 
observed that they generated a significantly lower active force at optimal stretch compared to 
the controls (Fig. 4 in Paper I). The length-force relationship was not affected by 
knockdown, suggesting that the altered filament spacing or the disrupted structural links did 
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not influence the length dependency of filament overlap. We estimated the active stress (i.e. 
the force per muscle cross sectional area) and conclude that a smaller muscle size was a 
contributing factor for the weaker contraction in the desmin morphants, but not the sole 
explanation (i.e. the reduction in force was larger than expected from the decrease in cross-
sectional area). We also addressed the question if the wider filament spacing in the desmin 
morphants could explain the lower tension (Fig. 4 in Paper I), and showed that osmotic 
compression of the morphants to the spacing in controls did not rescue the impaired force and 
that swelling of controls to the level in the morphants did not lower tension. These findings 
thus support that the role of desmin in muscle contraction is mainly associated with the force 
transmission, by anchoring and integrating the sarcomeres as contracting units. Most likely 
lack of the desmin/intermediate filament attachments affect the force transmission between 
the muscle and myosepta, consistent with a proposed role in myotendinous junctions in 
mammalian muscle (Tidball, 1992). A further consequence of an affected Z-disk anchoring in 
the desmin morphants can be changes a lack of coordination of contractile unit lengths during 
contractions as discussed previously for smooth and striated mammalian muscle (Balogh et 
al., 2003; Sjuve et al., 1998). Previous work on the mechanical role of desmin has to a large 
extent been based on studies of desmin knock-out animals, as discussed above. An interesting 
aspect of the zebrafish morphants is that we show that ~50% reduction in desmin is sufficient 
to introduce both structural (Section 4.1.2) and contractile impairments.  
In a previous study on the desmin knockout mouse (Sam et al., 2000), it was reported that 
these animals, although they had a lower active tension, were less affected by eccentric work 
(i.e. when muscles are stretched during contraction). We therefore established a protocol for 
eccentric contraction in the zebrafish larvae. Isometric tetanic contractions (i.e. without 
stretch) could be repeated 10 times with only moderate decrease in active force (Fig. 5 in 
Paper I). When we applied a lengthening step at the plateau of contraction, such repeated 
eccentric contractions resulted in a decrease in active tension of about 40-60% after 10 
contractions in control larvae. In contrast, the desmin deficient morphants were less affected 
(~15-20% decrease) under the same conditions. The relative force increase during the stretch 
was similar in controls and morphants, showing that the challenge to the muscles was of the 
same magnitude. These findings suggest that the susceptibility of skeletal muscles to stretch 
is affected by the mechanical link inside cells provided by desmin. It has been shown that 
desmin is one of the proteins primarily degraded after eccentric work in some animal models 
(Barash et al., 2002), possibly reflecting that the protein is strained during eccentric stretch. It 
has been shown that swelling of muscle fibers lowers the resistance to stretch (Edman, 1999) 
and another interesting possibility is that the wider filament spacing in the desmin morphants 
might be protective against stretch induced injury, by allowing slipping of filaments in the 
sarcomeres and less injury during stretch.  
4.2 DYSTROPHIN - DUCHENNE MUSCULAR DYSTROPHY  
As presented in Introduction (1.2.2), Duchenne Muscular Dystrophy (DMD) is a severe 
muscle disorder of genetic origin. Mutations in the dystrophin gene have been identified in 
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DMD patients, leading lack of functional dystrophin expression (Aartsma-Rus et al., 2006). 
As illustrated in Figure 11 above, loss of dystrophin would compromise the dystrophin-
glycoprotein complex, leading to an interruption of the structural link between membrane and 
contractile components in muscle. Significant experimental work has been invested into this 
field; human studies, as well as canine and transgenic mouse (mdx mouse) models have been 
extensively explored (Bieber and Hoffman, 1990; Dangain and Vrbova, 1984; Howell et al., 
1997). Several pathological mechanisms, e.g. membrane injury, oxidative stress, cellular 
signaling (Bhatnagar and Kumar, 2010; Lynch et al., 2000; Whitehead et al., 2006) are 
implicated in the disease progression, but still not fully understood. No cure for the disease is 
currently available. In Paper II we examined the Sapje zebrafish model for DMD and 
examined the effects of a novel therapy based on a read-through compound and in Paper III 
we further examined the effects of active muscle contraction on disease development, also in 
comparison with a laminin deficient strain (Section 4.3).  
4.2.1  The Sapje/DMD zebrafish 
Like the mdx mouse, the Sapje (dmdta222a) zebrafish carries a point mutation in the dystrophin 
gene, resulting in a pre-mature stop codon (Bassett et al., 2003). This mimics the general 
situation in human DMD patients, where functional dystrophin is lacking and also 
specifically the case in ~15% of the human DMD patients where non-sense premature stop 
codon mutations are present (Tuffery et al., 1998). Interestingly, unlike the mildly affected 
mdx mice, the Sapje fish have generally more severe muscle phenotype and shortened 
lifespan, which may provide an alternative and possibly better model for human DMD. 
 
  
 
Figure 13. Schematic structure of the zebrafish dystrophin/dmd gene and the location of the point 
mutation in Sapje (dmdta222a). The nonsense mutation (A-to-T) is located in exon 4 (indicated with 
arrow), causing the pre-mature termination of protein translation.  
As an indication of the muscular dystrophy in the Sapje zebrafish larvae, the mutants reveal 
patchy alterations under birefringence microscopy (Bassett et al., 2003; Fig. 1 in Paper II). 
These defects appear clearly at 3 dpf, providing a useful assay to differentiate the 
homozygous mutants from the siblings at this developmental stage. We confirmed using 
genotyping that the mutants identified with birefringence had the expected genotype. We also 
used Western blotting and immunostaining (Fig. 4 in Paper II) and showed that no 
dystrophin was expressed in the Sapje mutants. 
To further investigate the structural alterations, especially the areas showing birefringence 
defects, we examined the general muscle morphology with F-actin staining (Fig. 4 in Paper 
II). The mutant larvae had well-preserved striations, but significantly altered muscle 
architecture; specifically, the muscle fibers appeared disarrayed with more space between the 
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bundles. The structural alterations seemed to be localized in certain somites, as shown by 
patchy damages under the birefringence assay. These morphological changes indicate that the 
dystrophin-null cells in the somites are damaged and undergo degeneration and necrosis. The 
structural damage started to develop from 3 dpf, when larvae start to hatch and swim, 
suggesting the progressiveness of the disease and its association with activity/movement (cf. 
Section 4.2.4). This is consistent with results from the mdx mice (Lynch et al., 2001) and 
possibly also human patients, showing that muscle activity partly contributes to disease 
progression. This aspect is further discussed in relation to the immobilization experiments. 
4.2.2 Sapje/DMD zebrafish have impaired contractile function 
In order to translate the zebrafish model to human disease, characterization of muscle 
function is essential. In Paper II, the active force generation was examined in 4-5 dpf Sapje 
larvae, to examine the muscle contractile performance. The homozygous mutated Sapje 
larvae were identified according to the birefringence defects and compared to the control 
siblings. To exclude any difference due to genetic background in the control group, we 
genotyped a group of control siblings after mechanical analysis, and found no difference in 
the function between wild type and heterozygous animals. The homozygous Sapje mutants 
generated significantly lower active force, with slower force transients during contraction and 
relaxation, compared to the siblings (Fig. 2 in Paper II).  The reduction in active force can be 
partly related to a slightly smaller size, but the decay in force was larger than expected from 
the smaller muscle cross-section, and in view of the structural changes it is likely that muscle 
damage and loss of contractile tissue is a major contributing factor for the contractile 
impairment, as proposed for the mouse mdx model and humans (Lynch et al., 2000). In the 
mdx model, muscle damage is larger in active muscles and increases with age, suggesting 
activity-induced disease progression (Lynch et al., 2001). The mdx mice are less affected 
compared to the human patients, possibly related to compensatory mechanisms (Matsumura 
et al., 1992) or higher regeneration capacity (Megeney et al., 1996). In that aspect the Sapje 
larvae are more affected and thus possibly more similar to the human situation. Since the 
variations caused by age, muscle activity and fiber type composition are minimal in the Sapje 
zebrafish, these animals thus provide a well-defined model. 
4.2.3 Ataluren partially restores the protein expression, improves muscle 
structure and function in the Sapje/DMD model 
As discussed above, although significant efforts have been made, there is still no cure for the 
DMD patients. The zebrafish models make it possible to screen novel therapeutic regimens in 
a comparatively rapid and simple manner, with a clinically relevant functional readout. 
Ataluren (PTC124) is a small-molecular compound, which like some of the aminoglycoside 
antibiotics, has been proposed to enable the read-though of non-sense stop codon mutations 
(Barton-Davis et al., 1999; Pichavant et al., 2011). In the case of DMD, this type of mutations 
constitutes about 15%, which suggest that Ataluren can be an attractive treatment. It has been 
shown that Ataluren promotes the nonsense read-through in vitro, and improves mdx mouse 
muscles with low toxicity (Welch et al., 2007). The compound was examined in a first 
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clinical trial on a small number of DMD patients and, although no side effects were noted, the 
dose-dependency was complex, with no effect of a higher dose (Peltz et al., 2013). This 
temporarily halted further clinical trials and introduced a need for further examination of the 
dose-effect relationship.  
In Paper II, we first examined the contractile function in the Sapje/DMD model (Section 
4.2.2), and then examined the effects of Ataluren. The treatment started at 3 dpf, when the 
Sapje larvae hatch and start to swim freely. The Sapje mutants and their normal siblings were 
selected and grouped according to the birefringence assay. The treatment lasted from 3 to 5 
dpf with a concentration range of 0-35 µM Altaluren. 0.1% DMSO was applied as a solvent 
control. The animals were examined with force measurements and analysis of structure and 
dystrophin expression at 5dpf. During the treatment, the larvae were kept one per each well in 
a 24-well plate. The DMSO control and Ataluren did not have negative effects on animal 
behavior or contractile function, except for the highest dose of Ataluren (35µM), where both 
control and Sapje larvae groups had an increased mortality. The two-day treatment with an 
optimal dose of Ataluren (0.5 µM) partially increased the dystrophin protein expression, as 
detected with Western blotting (Fig. 4, Paper II), showing that the read-through compound 
was effective in the zebrafish model. In addition, immunostaining on the treated larvae 
showed recovery of staining of dystrophin along the cell membrane in the somites in treated 
Sapje larvae. In contrast the non-treated Sapje completely lacked dystrophin expression. 
 
 
Figure 14. Summarized results of functional and structural rescue by Ataluren in Sapje mutant larvae.  
Left: dose-dependency of Ataluren (0-35 uM) on the force generation; grey bars: healthy siblings; 
black bars: Sapje group. Right: structural recovery and protein restoration in the Sapje mutants with 
Ataluren (+A) at optimal dose. Modified from Paper II. 
We showed that the muscle contractile function of the Sapje mutants was significantly 
improved after Ataluren treatment. The active force of Sapje muscles increased from ~40% 
of the control to ~70% at the optimal dose (0.5 µM). However, the birefringence defects 
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remained in all Sapje groups even after treatment, suggesting that some muscle damage can 
occur already before 3 dpf or that a small decrease in dystrophin is sufficient to cause muscle 
injury. As discussed in relation to our immobilization experiments (Paper III, Section 4.2.4), 
active muscle contraction appears to be a major factor in the development of structural 
damage. Our data show that although Ataluren is effective in the Sapje model, the therapeutic 
concentration window of Ataluren is fairly narrow in the zebrafish larvae; beneficial effects 
appeared to be between 0.1 to 1 µM, while a higher dose (5 µM) lacked effects and even 
higher doses (35 µM) caused significant negative effects. This bell-shaped dose dependency 
demonstrated in the in vivo zebrafish model (Paper II) using a functional readout has also 
been seen in myotubes from patients and mdx mice (Finkel et al., 2013; Welch et al., 2007). 
This property might explain lack of effects in the first clinical trials and suggest a careful 
consideration of applied dosage in future clinical trials. Recently, the compound is in an 
active stage of development (Bushby et al., 2014; Ryan, 2014) and a new clinical phase III 
trial has been initiated (NCT01826487).  
4.2.4 Immobilization during early development prevents muscle damage in 
Sapje/DMD larvae 
The disease mechanisms in DMD are complex; several factors are proposed to play a role in 
the pathogenesis (Introduction section 1.2.2). The primary cause is the lack of dystrophin due 
to genetic mutations. Given the position of the dystrophin protein, and its associated 
dystroglycan complex (DGC, Figure 1), an impaired mechanical link of the intracellular 
components to the membrane has been proposed as a major mechanism (Brooks, 1998). The 
question: to what extend does the loss of the mechanical reinforcement by dystrophin 
contribute to the disease?, remains unresolved. Immobilization of muscles would be one 
approach to study this question. However, immobilization of hindlimb muscles in vivo using 
several different approaches have shown variable results in mdx mice (Hourdé et al., 2013; 
Mokhtarian et al., 1999). These previous studies on mice models have mainly focused on the 
later disease progression phase rather than the early onset, which raises another question - 
whether the early blocking of mechanical stress alone would abolish the pathological 
alterations in DMD.  
We observed in Paper II that the structural damages were observed in the Sapje mutant 
larvae at 3 dpf. Since the embryos establish motor function and start to move at about 18 hpf, 
it is possible that two days of physical movement (18 hpf to 3dpf) is sufficient for introducing 
a structural damage. This property gives a time window when the early phases of disease 
development and the role of active contraction can be investigated in the DMD zebrafish 
model. The zebrafish also offers unique possibilities compared to mammals, since the 
animals can be completely immobilized without considering effects on respiration and 
cardiac function. Also early developmental stages can be affected since they develop “ex 
utero”. The specific role of mechanical stress in early development of DMD was investigated 
in Paper III. We used a pharmacological approach, where all active skeletal muscle 
contractions, as judged by larval movement, were abolished for 3 days using the small 
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molecule actomyosin inhibitor BTS (Pinniger et al., 2005). The treatment was started at 18 
hpf before any physical movements occurred, and continued until 4 dpf when the muscle 
structure and function were analyzed. Since hatching of the larvae requires active contraction 
we manually hatched the larvae at 18 hpf. 
During the BTS treatment period, the larvae developed essentially normally with regular 
heartbeats and blood circulation, although the larvae were non-responsive to touch. No edema 
was observed in the heart or intestines. The body length of these immobilized larvae was 
similar to the larvae treated with 0.1% DMSO solvent control (Table 1 in Paper III) showing 
that the growth rate was essentially normal. When the treatment was terminated at 4 dpf, the 
larvae were transferred to regular E3 medium. Under these conditions when BTS was 
removed they started to swim freely after ~0.5 hrs, which shows that the BTS immobilization 
effects are reversible. We observed that BTS treated Sapje larvae did not develop any 
structural damages under birefringence assay. To confirm that these Sapje larvae were of the 
correct genotype, all groups were genotyped at 4 dpf. A more detailed structural examination 
using Rhodamine phalloidin staining did not reveal any difference between the BTS treated 
Sapje larvae and their siblings; the characteristic muscle fiber disarrangement and distortion 
in the non-treated Sapje mutant larvae were absent (Fig.1 in Paper III). This shows that the 
structural damage in the Sapje larvae is caused by mechanical activity, most likely via rupture 
of membrane sites (Bassett and Currie, 2004). 
We also observed that the general fiber alignment between the somites appeared slightly 
wavy in all BTS treated larvae, sibling controls and Sapje. This suggests that BTS treatment 
and immobilization has a general effect on muscle structure, indicating an association 
between mechanical silencing and altered-myofibrillogenesis, consistent with suggestions 
that cross-bridge cycling is crucial for the early myofibril development (Ramachandran et al., 
2003). The results show that although BTS appears to have a general effect on muscle 
structure, the treatment abolishes the structural damage in the Sapje larvae. In addition to the 
structural rescue, the difference in muscle function between the Sapje mutants and their 
normal siblings was also absent after BTS immobilization (Fig. 4 in Paper III). The maximal 
active force measured after BTS washout at 4 dpf was similar in the Sapje mutants and their 
siblings. Nevertheless, there was a general muscle weakness caused by BTS immobilization 
in both groups compared to the DMSO controls. This shows that immobilization clearly 
affect contractile function possibly related to the impaired myofibrilllogenesis as indicated by 
the wavy fiber arrangement observed after F-actin staining. We did not explore the nature of 
the lower active tension after BTS treatment, it might relate to changes in the myofibrillar 
arrangement or in establishment of the myofilaments. It is interesting to speculate of this 
mechanical and structural changes after immobilization, in some aspects resemble changes 
observed in human patients after long-term intensive care with pharmacological 
immobilization, the critical illness myopathy (Friedrich, 2006; Larsson, 2008). The general 
contractile impairment after BTS treatment was reversible since active movements 
reappeared after washout in E3 medium (cf. Section 4.3.4), although the extent of recovery 
and the time course in this model require further studies. 
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From a therapeutic perspective, the immobilization could be beneficial in DMD since the 
muscle cells might remain protected from membrane rupture, thus preventing the secondary 
damage responses, e.g., the Ca2+/Na+ influx, cell necrosis, inflammation, etc (Bhatnagar and 
Kumar, 2010). It should be noted that we used a complete immobilization not easily achieved 
and maintained in humans, and that the immobilization, also introduced an impaired muscle 
contractile function in controls with structural changes possibly by affecting activity-induced 
effects on myofibrillogenesis. Although full immobilization thus cannot be directly translated 
to a clinical setting in humans, the study indicates a mechanical effect in the pathogenesis of 
DMD, which might have an impact on the use of physical activity and exercise in DMD 
treatment. 
In summary, we found that muscle contractions and free movements are responsible for the 
structural alterations observed in Sapje mutants. Early intervention by blocking contractions 
alone could abolish the onset of structural changes in the larvae.  
4.3 LAMININ - CONGENITAL MUSCULAR DYSTROPHY 
Congenital muscular dystrophy (CMD) is a heterogeneous group of neuromuscular disorders, 
with early onset and variable progression (Iannaccone and Castro, 2013). Like in DMD, 
genetic sequencing analyses have identified genetic mutations in several proteins. One 
common subgroup of CMD, the “merosin-deficient congenital muscular dystrophy type 1A” 
(MDC1A), is due to loss of the laminin α2-chain (also known as merosin). Laminin is an 
extracellular component linking the dystrophin glycoprotein complex to the extracellular 
matrix (Figure 1). The molecular mechanisms underlying the pathological progression are 
however not clear yet. Different mouse models have been studied. Some strains contain low 
amounts of laminin, exhibiting a mild phenotype (dy/dy, dy2j/dy2j), and compensation from 
truncated laminin α2-chain was observed in dyw/ dyw mice (Guo et al., 2003); thus, the 
complete lack of laminin α2-chain conditions observed in humans have not been fully 
resembled.  
4.3.1 Laminin α2-chain deficiency in Candyfloss zebrafish strain 
The Candyfloss (Caf) zebrafish strain has recently been identified as a model for MDC1A. 
These mutants carry a non-sense mutation in LAMA-2 gene, resulting in no expression of 
laminin-α2 via non-sense mRNA decay (Hall et al., 2007). The location of the mutation is a 
homologue to human exon 60, at the globular domain. The phenotype of the Caf mutants was 
severe in the musculature with fiber detachment and degeneration, and the animals die 
prematurely at between about 14-20 dpf. 
4.3.2 Alterations in muscle structure and functional defects in Caf larvae  
The Caf/MDC1A mutants have several similarities with the Sap/DMD strain: 1) The general 
development of Caf mutant larvae is essentially normal, with no major abnormalities 
observed in heart or other organs. 2) They develop severe structural defects in muscle at 
about 3 dpf. The muscle cell differentiation of Caf mutants is unaltered, and the structural 
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lesions in skeletal muscles develop from 36 hpf with full penetration at 3 dpf. 3) The 
reduction of muscle birefringence is significant, with a patchy/uneven distribution. With 
Rhodamin-phalloidin staining, the general muscle fiber organization is distorted 
stochastically in the 4 dpf Caf larvae (Paper III). Overall, the structural alterations in the Caf 
/MDC1A model thus appear similar to the defects observed in Sapje DMD model, but with a 
larger magnitude as shown in the quantification of the birefringence intensity (Fig. 3 in Paper 
III). To understand the consequence of these observations in muscle function, we carried out 
a mechanical analysis on the Caf strain. The Caf mutants generated significantly lower active 
force compared to their siblings at 4 dpf and 5 dpf, showing that alterations in the 
extracellular laminin attachments leads to both structural and functional impairment. 
Interestingly, the normal Caf siblings were weaker compared to the Sap siblings at 4 dpf, but 
became equally strong at 5 dpf (Fig. 4 and 5 in Paper III). This might suggest a difference 
underlying the genetic background of the two strains as discussed below in 4.3.4. 
4.3.3 Contraction-induced injury plays a part in the pathogenesis of MDC1A 
The laminin-α2 chain is an essential ligand to α-dystroglycan of the DGC complex. As an 
extracellular part of the DGC integral system, laminin is shown to stabilize the cell membrane 
and protect the muscles from mechanical stress (Han et al., 2009). In addition to the 
mechanical strengthening role, laminin-α2 chain also binds to integrin-7, promoting the cell 
survival (Vachon et al., 1997). It has been proposed that the mechanical contraction-induced 
fiber detachment from the extracellular matrix is the initial cause for the MDC1A in the Caf 
zebrafish (Hall et al., 2007). In that study, a short-term immobilization (up to 3 dpf) of the 
Caf mutants with Tricaine was shown to prevent the disease phenotype. However, detailed 
analysis on the immobilized muscles was absent. In addition, the paralyzing effect from 
Tricaine is on the voltage-gated Na+ channels, non-specific for the muscle contractions, and 
might include secondary effects in the muscles. To further investigate this, we applied the 
BTS immobilization protocol as described above (Section 4.2.4) to the Caf in comparison 
with the Sap larvae. BTS, specifically inhibit the cross-bridge cycling in skeletal muscles 
without non-selective effects on other cell types or intracellular organelles (Cheung et al., 
2002; Pinniger et al., 2005). The treatment of Caf mutants was between 18 hpf to 4 dpf, and 
the larvae were kept fully immobilized during the period. The structural alterations were 
completely abolished, as shown with birefringence and Rhodamine phalloidin examination 
(Fig. 2 in Paper III). This shows that the mechanical injury via active contractions is a key 
pathological mechanism and that complete lack of laminin in Caf zebrafish mutant is not 
sufficient to cause muscle damage in the absence of mechanical stress.  
4.3.4 Strain differences in muscle activity affects development of muscle 
lesions 
Inter-strain difference is an important consideration in biomedical research on animal models. 
For the zebrafish, Tübingen (TU) is the main wild-type strain for the genome sequencing and 
phenotyping (Haffter et al., 1996; Haffter and Nüsslein-Volhard, 1996) and was used in 
Paper I and IV. For the mutated strains studied in Paper II and III, the normal siblings for 
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dystrophin and laminin were used as controls. We did not observe any differences between 
the heterozygotes and the wild type larvae. However, in Paper III we observed a generally 
more active swimming behavior in the Caf zebrafish control larvae compared to that of than 
the Sapje controls. At 5 dpf, the total swimming duration was longer in the Caf controls 
(Table 2 in Paper III), which suggest that these animals were more mechanically active. The 
muscle activity might be involved in the growth in strength in Caf siblings from 4 to 5 dpf 
(Fig. 4 and 5 in Paper III), compared to the Sapje group, where the difference in active force 
between 4 to 5 dpf was minor. Interestingly this might relate to the appearance of structural 
injury after BTS immobilization. Both the Sapje and Caf strains were rescued, with regard to 
birefringence alterations, by the BTS immobilization with no structural damage observed at 4 
dpf. However, the Caf developed birefringence lesions at 5 dpf after one-day recovery and 
activity. In contrast, the Sapje BTS group appeared essentially normal under birefringence at 
the same stage (5 dpf). This difference seems to relate to the difference in swimming activity. 
These data from recovery after immobilization further demonstrate that muscle contractions 
and swimming activity are associated with both DMD and MDC1A development in the 
zebrafish, and that the mechanical stress is an initial pathological factor. 
4.4 MYOSIN BINDING PROTEIN C - STRIATED MUSCLE MYOPATHIES  
The sarcomeric protein, Myosin Binding Protein C (MyBPC), has been extensively studied as 
a candidate for human familial cardiac hypertrophy (Watkins et al., 1995). Several mutations 
have been identified in the cardiac MyBPC (MyBPC-3) and the protein has several regulatory 
phosphorylation sites (Finley and Cuperman, 2014). In skeletal muscle, two isoforms of the 
protein are identified, slow (MyBPC-1) and fast (MyBPC-2). The structure of the different 
isoforms is fairly conserved (Oakley et al., 2004) and the cellular location and molecular 
interactions are similar to that of the cardiac MyBPC (Luther et al., 2008). The function of the 
skeletal isoforms is less well characterized. The slow MyBPC-1 has been linked to human 
muscle disease (Gurnett et al., 2010; Markus et al., 2012). The function of the fast skeletal 
isoform and a possible relation to muscle disease is less understood. In Paper IV, we applied 
the reverse-genetic approach as in Paper I, using morpholino antisense oligonucleotides in 
zebrafish early larvae, to knock down the skeletal MyBPC content, and investigate the 
consequences in vivo. 
4.4.1 Partial loss of fast skeletal MyBPC-2 results in a severe muscle 
phenotype 
We identified three genes for skeletal MyBPCs in the zebrafish, one slow (MyBPC-1) and 
two fast (MyBPC-2A; MyBPC-2B). Since pseudogenes often occur during gene duplication 
in the zebrafish we first examined the expression of all three genes. We determined the 
mRNA levels in the zebrafish larval trunk muscles using RT-PCR at different developmental 
stages of the larvae, including 1, 3 and 7 dpf (Fig.1 in Paper IV). The cardiac MyBPC-3 was 
not found, and the MyBPC-2A appeared non-transcribed at all times. The MyBPC-2B was 
the most dominant skeletal MyBPC isoform and was expressed already at 1 dpf. The mRNA 
for the slow type, MyBPC-1, was also present but at lower amounts.  
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To investigate the function of the MyBPC proteins, we applied a knockdown approach in 
early larvae as described in Paper I (Section 4.1.1). The morpholino antisense 
oligonucleotides (MO) were designed to target either the splicing or translation process of 
mRNA. In Paper IV, in addition to the standard control MO, the MO against MyBPC-2A 
also served as an internal control, since this isoform is not expressed. Similar to the 
knockdown effects achieved for desmin in Paper I, the MOs used in this study reduced the 
mRNA and protein content (for MyBPC-2 by about 50-70%, determined by RT-PCR and 
silver-stained protein gels (Fig. 2 in Paper IV). Knockdown of the fast MyBPC-2B gave a 
severe phenotype the larval muscles (Fig. 3 in Paper IV). We observed significant structural 
changes in the sarcomerers and filament arrangement as discussed below. The MyBPC-2B 
morphants also revealed signs of delayed development, cardiac edema, and had a high 
mortality rate compared to the controls. The contractile function was significantly impaired as 
discussed below (Section 4.4.4). The results thus show that knock down of the fast skeletal 
MyBPC-2 in the zebrafish results in a marked myopathy. To our knowledge, human skeletal 
myopathies associated with altered MyBPC-2 or animal models have not been described, and 
we can at present not make comparisons with any myopathies in other species. However, 
mutations in human MyBPC-1 gene have been associated with distal arthrogryposis (Gurnett 
et al., 2010) and congenital contractural syndrome type (Markus et al., 2012). Our study was 
focused on the fast MyBPC-2 form, but we also examined effects of knockdown of the slow 
MyBPC-1. Our analysis revealed that the MyBPC-1 morphants were essentially normal 
compared to the controls at 4dpf (Fig. 3 and 5, Paper IV). The minor effect of MyBPC-1 
knock down was possibly due to the muscle type composition. In the zebrafish, slow muscle 
fibers only form one single layer underneath the skin; the rest of the myotome is essentially 
fast (Bryson-Richardson et al., 2005). Assuming that the fast and slow MyBPCs are fiber 
type specific, the decrease in MyBPC in the slow fibers might not have an impact. Slow 
fibers have been shown to be dominant at earlier developmental stages (Blagden et al., 1997) 
and our data further show that MyBPC-1 is not essential for the development of the trunk 
muscles. We did not observe any effects on contractile function after MyBPC-1. These 
results showing minor effects of MyBPC-1 knock down are different from a study showing 
negative effects on muscle structure following MyBPC-1 knock down in the zebrafish (Ha et 
al., 2013). We have no explanation for this difference, which might relate to the different 
design and amount of the MOs. We are, however, confident that we have a selective 
knockdown of MyBPC-1 by about 80% without effects on the MyBPC-2 expression or 
muscle structure.  
4.4.2 Structural alterations and elevated degeneration/apoptotic signaling in 
MyBPC-2 morphants 
Unlike in the desmin morphants (Paper I) or the muscular dystrophy mutants (Paper II, III), 
the structural alterations in the MyBPC-2 morphants involved marked changes in the 
sarcomere length distribution. As shown with Rhodamine-phalloidin staining, the MyBPC-2 
morphants had clear striations indicating the presence of sarcomeres (Fig. 3 in Paper IV). 
However, the fiber arrangement was disordered and the sarcomere lengths were varied. The 
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quantification of the sarcomere length showed generally shorter sarcomeres with a wide 
distribution spectrum (Fig. 3 in Paper IV). This suggests that lack of MyBPC-2 results in a 
primary failure in sarcomere assembly.  
The inter-fiber space was also widened, with gaps between muscle bundles, in the MyBPC-
2B morphants compared with the control group (Fig. 3, Paper IV), suggesting muscle 
degeneration or apoptosis. Apoptotic changes were also higher in the MyBPC-2B morphant 
larvae as revealed by Acridine orange staining (Fig. 4, Paper IV). To further explore this 
possibility we examined expression of signaling components in degeneration using RT-PCR 
(Fig. 4, Paper IV). The transcription factors MuRF1-3, LCB3, SQSTM1 all associated with 
degeneration in the skeletal muscles (Cohen et al., 2009; McElhinny et al., 2004; Perera et al., 
2011) were significantly upregulated. We also found that myogenin expression was two-fold 
upregulated compared to the control groups, suggesting activation of regeneration signaling 
(Onofre-Oliveira et al., 2012). These data thus show that lack of MyBPC-2 significantly 
affects muscle structure with activation of degeneration/apoptosis and regeneration, and with 
altered assembly of sarcomeres. At present we cannot provide data on the mechanism how 
lack of MyBPC-2 induces these alterations. Knockdown of MyBPC-2 results in lower active 
force in a similar manner as for desmin knockdown, but appears to have key functions also in 
signaling for sarcomere assembly. It should be noted that MyBPC has links to titin (Okagaki 
et al., 1993), which has signaling to the nucleus (Lange et al., 2005), and it is possible that 
MyBPC in some manner provides links between mechanical events in the sarcomere and 
signaling for sarcomere assembly or muscle degeneration/regeneration (Yang et al., 1998).   
Despite the muscle damage early during sarcomere assembly, the structural failure in 
sarcomeres and large degenerative process were not accompanied by any increased fibrosis, 
since the Sirius red staining for collagen showed similar intensity in both groups 
(supplementary data, Paper IV). Fibrosis is often observed in muscle degeneration (Balogh 
et al., 2002; Ho et al., 2010; Stedman et al., 1991) and the findings in the MyBPC-2 
morphants can reflect that we are studying comparatively early events in the degeneration 
process.  
4.4.3 X-ray diffraction studies of MyBPC-2 morphants 
To further characterize the structural alterations in the muscles with MyBPC-2 knockdown in 
Paper IV, we carried out X-ray diffraction experiments as described in Paper I. The X-ray 
patterns of the larval preparations were recorded in single larvae and we observed strong 
equatorial reflections (11, 10). At present the resolution of the meridional pattern was poor. 
This can be due to the orientation of the muscle fibers, which is essentially parallel with the 
larval long axis, but with some angular distribution. This can obscure the weaker meridional 
parts of the pattern and meridional layer lines. Our first experiments in Papers I and IV were 
performed at the A2 beamline HASY-lab, Hamburg that had comparatively larger focus (300 
x 2000 µm), which gave strong signals but exposed a larger fraction of the larvae. Later 
experiments in Papers II and IV were done at the MaxIV laboratory, Lund which enabled a 
smaller focus (100 x 100 µm), thus illuminating a smaller part. This gave somewhat better 
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meridional patterns with the myosin 14.3 nm reflection visible in some samples, although not 
with a resolution enabling identification of the 44.2 nm MyBPC reflection (Rome et al., 
1973) visible. We could thus not demonstrate a change in this reflection or in the myosin 
reflections following knock down of MyBPC-2. The meridional MyBPC reflection has been 
examined early in rabbit skeletal muscles (Rome et al., 1973), showing a periodicity at 44.2 
nm. It is possible that further work on the zebrafish larval samples using other X-ray sources 
with smaller focus might resolve also other parts of the X-ray pattern. 
Our main readout was the equatorial reflections (d10, d11) and their intensity ratio (I11/I10) 
reflecting the interfilament distances and the mass transfer between the thick and thin 
filaments, respectively (Haselgrove and Huxley, 1973; Millman, 1998). For interfilament 
spacing determination, the larvae were examined under different degrees of stretch and 
osmolarity (Fig. 7 in Paper IV).  The muscles were first examined at an optimal stretch for 
active force. At low external osmolarity, the lattice spacing was wide and similar in both 
control and MyBPC-2 morphants suggesting that lack of the MyBPC does not affect the 
maximal lateral expansion of the lattice. However, when osmolarity was increased, to that in 
the standard Krebs-Ringer medium and above, the MyBPC-2 morphants were less 
compressed and the lattice was significantly wider. X-ray studies have been performed on 
cardiac muscle from MyBPC-3 knockout animals showing conflicting results (Colson et al., 
2007; Palmer et al., 2004; Palmer et al., 2011). Our data suggest that absence of MyBPC 
affects the lateral coupling between the contractile filaments, so that lack of the protein 
removes a component keeping filaments together. This finding further supports the linkage 
role of MyBPC between actin and myosin filaments. 
When the muscle was stretched the lattice was compressed in both controls and MyBPC-2B 
morphants (Fig. 7 in Paper IV) reflecting a constant volume behavior (Edman, 1999). In 
conclusion the structural and X-ray data suggest that the lack of MyBPC-2 results in shorter 
and expanded sarcomeres.  
We used the intensity ratio of the equatorial reflections to examine the myosin head 
movements and positions. Cross-bridge movement out from the myosin filament towards 
actin is considered to increase the outer 1.1 reflection and decrease the inner 1.0 reflection 
giving an increased 1.1/10 intensity ratio (Haselgrove and Huxley, 1973). When a rigor state 
was induced by NaCN treatment a marked increase (about 4 times compared to the relaxed 
signal) was observed. We assume that all cross-bridges attach under these conditions and 
used the rigor value for normalization. We first examined the intensity ratio in the relaxed 
state and found that the intensity ratio, relative to the rigor value, was increased in the 
MyBPC-2B morphants. This can reflect that absence of MyBPC-2 results in an outward 
movement of the myosin heads in the skeletal muscle. This might resemble the effects 
observed in from cardiac muscle where Protein Kinase A-mediated phosphorylation of 
MyBPC-3 near the N-terminus weakens the interaction between MyBPC and myosin-S2 
segment and results in outward movement of the myosin head (Colson et al., 2008).  
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To examine the motion of myosin heads during active contractions we developed a protocol 
where X-ray patterns were recorded in the relaxed state and during 200 ms tetani. Since about 
10s recording was required to obtain a sufficiently strong signal, we accumulated the pattern 
during 15 successive contractions only recording (by gating the detector) during the 
contractions. We observed a clear increase in the intensity ratio during contraction consistent 
with a previous report (Dou et al., 2008), but, interestingly, the tetanic contractions did not 
result in a large increase of the attached cross-bridges in the larval muscles when compared to 
the relaxed state. The intensity ratio in the active muscle was ~30% of that in rigor (Fig. 7 in 
Paper IV). A corresponding value in frog muscle is ~45% (Haselgrove and Huxley, 1973). 
This suggests that a comparatively low number of cross-bridges are attached during active 
contractions in the zebrafish muscles. This can reflect a generally fast cycling rate in the 
zebrafish skeletal muscles during active contraction where the high rate results in a short time 
when the cross-bridges are attached to actin as discussed above (Section 4.1.3) in relation to 
active force.  
In summary, the X-ray results suggest that skeletal MyBPC-2 affects the cross-bridge 
positions in the relaxed state, keeping them close to the thick filament. Lack of this structural 
constraint results in an outward movement. The MyBPC-2 morphant muscles also have an 
expanded lattice and shorter sarcomeres at optimal stretch. During active contractions cross-
bridges move out towards actin, but the relative number of attached heads in the fast 
zebrafish muscle is low, and we could not observe any major differences in the MyBPC-2B 
morphants in this respect.   
4.4.4 Contractile impairments in MyBPC-2 morphants 
In Paper IV, we characterized the contractile performance of the MyBPC-2 morphants. We 
first found that the maximal active force at optimal stretch was significantly decreased (Fig. 5 
in Paper IV) following the partial loss of MyBPC-2. A major contribution is the structural 
change with less contractile tissue most likely due to the degeneration processes described 
above. We also observed wider filament spacing (Section 4.4.3), but, as discussed in relation 
desmin and Paper I (Section 4.1.3), this change was not of a magnitude expected to influence 
the active force. Since we observed a major change in the sarcomeres towards shorter lengths 
and a wider length distribution (Section 4.4.2), we examined the length tension behavior (Fig. 
5 in Paper IV) and found a less steep ascending limb. The ascending limb of the length 
tension curve is complex and includes not only changes in filament overlap but also other 
filament interactions and alteration in the degree of activation (Rüdel and Taylor, 1971). The 
wider sarcomere length distribution in the MyBPC-2 morphants is likely a major contributing 
factor to the less steep relationship, although other factors, e.g. a change in the length 
dependency of filament spacing and Ca2+ sensitivity can be involved.  With regard to the 
latter factor, it has been shown the cardiac MyBPC-3 interacts with actin filaments and 
affects the thin filament regulation (Razumova et al., 2008) and our analysis of the single 
twitch force transients show that the rates of relaxation and contraction are altered in the 
MyBPC-2 morphants, possibly reflecting changes in activation/deactivation processes. 
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Early work on striated muscle MyBPC has suggested that the MyBPC is affecting the cross-
bridge cycling rate. This was based on studies of skinned skeletal fibers where extraction of 
the MyBPC resulted in an increase in the maximal shortening velocity (Vmax), which was 
reversed upon re-addition of the protein (Hofmann et al., 1991a). Further work using in vitro 
motility applying MyBPC-3 assays support this view (Saber et al., 2008) and are interpreted 
that the MyBPC tethers the myosin head to thick filament backbone (Calaghan et al., 2000; 
Colson et al., 2008). Recent work has to a large extent focused on the cardiac MyBPC-3 
based on knockout mouse models (Harris et al., 2002; Korte et al., 2003). In cardiac fibers 
from these animals it has been shown that the maximal shortening velocity is increased when 
the protein is absent or when it is phosphorylated (Colson et al., 2012; Harris et al., 2004; 
Kunst et al., 2000; Sadayappan et al., 2005). A corresponding regulation via phosphorylation 
has not been demonstrated in the skeletal MyBPC-2, which lacks two of the three 
phosphorylation sites, although other phosphorylation sites are present (Oakley et al., 2004). 
To our knowledge, knock-out mouse models for MyBPC-2 are not available and the knock-
down MyBPC-2 morphant thus enables an initial approach to examine the mechanical 
function of MyBPC-2 in intact muscle fibers. We therefore also attempted to examine if the 
maximal shortening velocity was altered after MyBPC-2 knock-down in skeletal muscle. 
Since the later phases of tetanic contractions in the larval preparations might involve 
fatiguing of a fast muscle component (Dou et al., 2008), we used single twitch contractions. 
Since these are very rapid we applied a velocity ramp protocol, so that contractions could be 
initiated a defined shortening velocities. Using this approach we evaluated force responses at 
different velocities and constructed force velocity relationships. The data points at 
intermediate velocities/forces are affected by the non steady state situation since the 
contractile component will shorten and stretch the series elasticity while developing twitch 
force. We therefore only evaluated the extrapolated maximal velocity by extrapolating to zero 
loads. This value is most likely is somewhat underestimated due to the less concave 
relationship. Using this approach we found a comparatively higher Vmax (~ 40% increased) in 
the MyBPC-2 morphants. A further complication in the analysis is the shorter sarcomere 
length (~18%) in the morphants, which would make the difference in velocity at the filament 
level smaller although still different (~ 14% higher in the morphants). With these 
reservations, we consider the velocity data to be consistent with a higher velocity upon 
removal of MyBPC-2 in skeletal muscle. 
4.4.5 MyBPC-2 associated myopathy 
Our data on MyBPC-2 knockdown in the zebrafish (Paper IV) show that partial removal of 
this protein results in a severe myopathy, characterized by muscle degeneration/regeneration 
and derangement of muscle fibers. At the level of the contractile apparatus, the sarcomeres 
are shorter and display a wider length distribution, and have a wider interfilament lattice 
spacing, These results can reflect a primary effect of MyBPC-2 on the regulation of filament 
assembly. The actin-myosin interaction is accelerated and the resulting force significantly 
lower. We are not aware of a human clinical condition associated with MyBPC-2 mutation. 
Since the phenotype following partial removal of MyBPC-2 in the zebrafish is comparatively 
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severe, it is possible that MyBPC-2 mutations are embryonic lethal, but the protein would 
still an interesting candidate for further search in skeletal myopathies of unknown origin. 
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5 CONCLUSIONS   
 
• The zebrafish larva is a suitable model for mechanistic studies of functional 
consequences of contractile and structural protein alterations in skeletal muscle. 
• The mechanical readout, in combination with structural data, provides a clinical-
relevant parameter that can be measured with high resolution, enabling structure-
function analyses in muscle diseases and screening of novel therapeutic approaches. 
• Partial loss of desmin in the skeletal muscle affects the lateral anchoring of contractile 
filaments and protects the muscle from force decay during eccentric contractions. 
• Loss of dystrophin in the Sapje zebrafish model of Duchenne Muscular Dystrophy 
(DMD) results in a significant muscle weakness, showing that interference with the 
membrane anchoring of the muscle cytoskeleton impairs muscle structure/function. 
• Ataluren, a read-though compound, partially rescues the contractile function in the 
Sapje/DMD larvae by restoring dystrophin protein expression and exhibited a 
biphasic dose dependency relating to findings in clinical studies. 
• Loss of laminin α2 chain in the Candyfloss zebrafish model results in a significant 
muscle weakness. 
• Both Sapje and Candyfloss mutant models are protected from structural injury by 
early immobilization, indicating that mechanical stress plays a primary role in disease 
development in muscular dystrophy. 
• Fast skeletal Myosin Binding Protein C (MyBPC-2) affects development, structure 
and cross-bridge interaction of the muscle sarcomere. Lack of this protein results in a 
severe form of skeletal myopathy. 
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